This sheet created by Arianna Schouten: ari	anna.schouten@keionline.org					
For background on KEI: http://keionline.org						
Vaccine Manufacturing Capacity sheet map	s the manufacturers currently involved	ed in COVID vaco	cine manufacturin	9		
Vaccine Manufacturing Possible Capacity sl	neet highlights potential COVID vac	cine manufacturin	ng facilities but als	o includes a numb	ber of other vaccin	e manufacturers
More information						
KEI page on vaccine manufacturing	https://www.keionline.org/covid-19	-vaccine-manufac	cturing-capacity			
KEI page on COVID-19 contracts	https://www.keionline.org/covid-co	<u>ntracts</u>				
KEI listerver on vaccine manufacturing	http://lists.keionline.org/mailman/li	stinfo/vaccine-mai	nufacturing_lists.k	eionline.org		
KEI Feb 19 roundtable on manufacturing	https://www.keionline.org/35271					
Examples of COVID-19 outsourcing/tech transfer deals	https://docs.google.com/spreadsh	eets/d/1ozD5-ebf7	7txIGQa0wpbVVX	krM3Nil04Quws5	OUhOSVA/edit?us	p=sharing

				B			
Country	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity	Location	Sources
Algeria							Little of the second se
A	Saidal	Manufacture (Sputnik)	VVnr			Constantine	https://www.reuters.com/business/healthcare- pharmaceuticals/algeria-start-russias-sputnik-v-vaccine-production- september-2021-04-07/
Argentina		Produce active		250 million doses in 2021 (in			
	mAbxience of INSUD Group	ingredient (AstraZeneca)	VVnr	conjunction with the facility in Mexico)		Garin and Munro	https://www.reuters.com/article/us-health-coronavirus-argentina- vaccine-idUSKCN25A2YI
	·			,			https://www.reuters.com/business/healthcare-
							pharmaceuticals/argentina-begin-sputnik-v-vaccine-production-after- getting-russian-ok-2021-06-02/?
	Richmond Laboratories	Manufacture (Sputnik)	VVnr				taid=60b7c021efd84f0001b64f89&utm_campaign=trueanthem&utm_medium=trueanthem&utm_source=twitter
Australia							Little of the control of the 19000 (and a finite and a fi
							https://www.cslbehring.com/vita/2020/csl-starts-manufacturing-a- potential-covid19-vaccine
						B	https://www.csl.com/news/2020/20201108-csl-commences-
	CSL	Manufacturing (AstraZeneca)	VVnr	30 - 50 million doses, beginning early 2021		Broadmeadows, Melbourne	manufacturing-of-university-of-oxford-astrazeneca-vaccine-candidate
							https://www.theaustralian.com.au/science/another-three-month-wait- for-cslproduced-covid19-vaccine/news-
		Fill and Finish					story/6af39c7e32b299acd5f7cfd2480fa19b https://www.segirus.com/news/csl-covid-19-vaccine-agreements-with-
	Seqirus (A CSL Company)	(AstraZeneca) Manufacturing (Griffith	VVnr	30 million doses	Capacity for bacterial and yeast	Parkville, Melbourne	australian-government https://luinabio.com.au/luina-bio-and-griffith-university-position-to-
	Luina Bio	University)	LAV		recombinant projects		develop-coronavirus-vaccine/
Austria					Limited ability to scale up	Klosterneuburg	
	Polymun Scientific Immun Biologische Forshung GmbH	Manufacturer of lipid nano particles (Pfizer)	RNA	Unknown	production Bottleneck in shipping product to Pfizer factory in Puurs	3	https://www.wsj.com/articles/if-one-leading-coronavirus-vaccine- works-thank-this-tiny-firm-in-rural-austria-11604664001
		Manufacture			Novartis is upgrading their plant to manufacture mRNA candidate		
	Novartis	(CureVac)	RNA	50 million doses 2021 200 million doses 2022	CureVac	Kundl	https://www.wsj.com/articles/novartis-to-help-make-curevac-covid-19- vaccine-11614859271
Bahrain		Manufacture (Sputnik					
	Mumtalakat	V)	VVnr				https://rdif.ru/Eng_fullNews/6865/
Bangladesh		Manufacturing own					
Belarus	Globe Biotech Limited	vaccine (Bongavax)	DNA	Unknown		Dhaka	
belarus							https://sputnikvaccine.com/newsroom/pressreleases/belarus-starts-
							vaccination-with-sputnik-v-/#:~:text=Belarus%20was%20the% 20first%20country.granted%20on%20December%2021%2C%
							202020.&text=RDIF%20and%20its%20partners%20are.of% 20Sputnik%20V%20in%20Belarus.
	Belpharmprom	Manufacture (Sputnik					. https://www.reuters.com/article/health-coronavirus-russia-belarus-
Belgium	(Belmedpreparaty)	V)	VVnr		Preparing for future production	Minsk	idUSKBN2930P6
Doigiani				000			https://www.catalent.com/catalent-news/catalent-to-showcase-
	Catalent Inc.	Fill and Finish (AstraZeneca)	VVnr	200 million units of syringe filling capacity per year		Brussels	aseptic-filling-expertise-and-patient-centric-dose-form-technologies- at-pharmapack/
				100 million between Puurs and Kalamazoo facility in the	This site is dedicated to COVID	Puurs	
	Pfizer	Manufacturing	RNA	US by the end of 2020	vaccine production		https://www.pharmaceutical-technology.com/comment/covid-19-
		Large scale VV				Seneffe	vaccine-manufacturing-disruptions/#:~:text="Novasep%20site"% 20cuts%20AstraZeneca%20vaccine%20production%20'by%2060%
	Novasep	manufacture (AstraZeneca)	VVnr	31 million doses in first quarter of 2021	Lines up to 2,000L		25'&text=It%20will%20now%20deliver%20only%2031%20million% 20doses.
		Manufacture		100 million doses in 2021(up	Emos up to 2,0002		
	GlaxoSmithKline	(CureVac) Manufacture Small	RNA	to)		Wavre	https://www.ft.com/content/56ef96f3-7433-484b-84fb-f67b3d8a5e47. https://ajibio-pharma.com/news-post/ajinomoto-bio-pharma-services-
	Ajinomoto Bio-Pharma Services	Molecule (AstraZeneca)	VVnr			Wetteren	expands-manufacturing-agreement-with-astrazeneca-to-include-drug- product-manufacturing/
Brazil					No. 6 - 22		
	B. de etc. Levin te		B//	100 million doses ready by	New facility construction underway - estimated by Jan 2020.	07. 8. 1.	https://www.reuters.com/article/us-health-coronavirus-brazil-sinovac- idUSKBN27P24K
	Butantan Institute	Manufacture (Sinovac) Manufacture	IV (possibly others)	September 2021.	2020.	São Paulo	https://www.reuters.com/article/us-health-coronavirus-brazil-vaccines-
	Fiocruz (Bio-Manguinhos)	(AstraZeneca) Manufacture (Sputnik	VVnr	200 million doses a year Up to 8 million doses a		Rio de Janeiro	in-idUSKBN29W141 https://www.reuters.com/article/us-health-coronavirus-brazil-sputnik-
	Uniao Quimica	V)	VVnr	month, as of 2021		Brasilia	idUSKBN29D2XM
	Tecpar	Manufacture (Sputnik V)	VVnr	Unknown		Curitiba	https://www.reuters.com/article/uk-health-coronavirus-brazil/brazilian- state-agrees-to-produce-russian-covid-19-vaccine-idUKKCN2582M8
Canada						Expected to be ready for	
	Biologics Manufacturing	Manufacturing				production in July 2021 - first vaccines will then	
	Centre	(Novavax)	VVnr, VVr, VLP & PS	2 million doses a month	4,000 L a month	be available early 2022	https://nrc.canada.ca/en/covid-19-response-building-infrastructure
	GlaxoSmithKline	Manufacturing adjuvant for Medicago	VLP	100 million doses by the end of 2021		SteFoy, Quebec	https://ipolitics.ca/2020/12/08/sanofi-wont-use-its-canadian-facility-to- make-a-covid-vaccine/
	Providence Therapeutics	Manufacturer	RNA	50,000 vials a day - each vial contianing 10 doses	Their vaccine candidate is ongoing clinical trails	Calgary, Alberta	https://globalnews.ca/news/7643740/canada-made-coronavirus- vaccine-providence-therapeutics/
	Therapure (now CDMO asset	Manufacturer (VBI					https://www.therapurebio.com/news/therapure-biopharma- inc/therapure-biomanufacturing-deal-with-vaccines-for-coronavirus-
Ohion		Vaccines)	VLP		136,000ft^2 cGMP facility	Mississauga, Ontario	vaccine-candidates
China		1		300 million doses a year in			
				2020 and increase capacity to an annual production of			
	Sinovac Biotech Ltd.	Manufacture (Sinovac)	IV	600 million doses Enough doses to inoculate at		Beijing	https://www.globaltimes.cn/content/1210460.shtml
	Tibet Rhodiola Pharmaceutical Holding Co.	Manufacture (Sputnik V)	VVnr	least 20 million people by 2021		Beijing	https://www.reuters.com/article/health-coronavirus-vaccine-russia-idUSKBN27R21E
		,				, ,	https://www.globenewswire.com/news-
	Shanghai Fosun Pharmaceutical Group Ltd	Manufacture (Pfizer)	RNA	100 million doses in 2021		Shanghai	release/2020/12/16/2145891/0/en/BioNTech-and-Fosun-Pharma-to- Supply-China-with-mRNA-based-COVID-19-Vaccine.html
							https://www.reuters.com/article/health-coronavirus-astrazeneca- kangtai-b/astrazeneca-in-deal-with-kangtai-bio-to-supply-potential-
							covid-19-vaccine-in-china-idUSL4N2F82BI
	Shenzhen Kangtai Biological	Manufacture	106			St	https://www.thechronicleherald.ca/news/world/astrazenecas-china- partner-expects-to-be-able-to-make-400-million-covid-19-vaccine-
	Products	(AstraZeneca) Manufacture (Sputnik	VVnr	400 million doses per year		Shenzhen	doses-a-year-547801/
	TopRidge Pharma Shenzhen Yuanxing Gene-	V) Manufacture (Sputnik	VVnr	100 million doses a year	Commercial production beginning		https://rdif.ru/Eng_fullNews/6681/
	tech	V)	VVnr	60 million	May 2021	Shenzhen	https://rdif.ru/Eng_fullNews/6675/
		L		300 million doses - 1 billion doses a year (when new			
	China National Biotec Group (Sinopharm subsidiary)	Manufacture (Sinopharm)	IV	manufacturing site completed)		Beijing & Wuhan	https://www.globaltimes.cn/content/1209776.shtml
	Sinovac (Dalian) Vaccine	Manufacture		Upwards of 20 million per		Dalian	https://www.sec. gov/Archives/edgar/data/1084201/000110465909067210/a09-
	Technology Co	(Sinovac)	IV, PS & LAV	year			34417_1ex99d1.htm https://www.prnewswire.com/news-releases/inovio-and-advaccine-
							announce-exclusive-partnership-to-commercialize-covid-19-dna- yaccine-candidate-ino-4800-in-greater-china-30120000.html#-:
	Advaccine	Manufacture (Inovio)	DNA	100 million per year		Suzhou	text=Advaccine%20will%20leverage%20its%20innovative.of%
	, wydourie	ariaracture (ITIOVIO)	D.M.	1.00 million per year	<u> </u>	CULTIVU	20DNA%20vaccine%20per%20year.

Country	Company	Eunetian	Vaccine Blotform	Production Quantity	Notes on Braduction Canacity	Location	Source
Country	Company	Function	Vaccine Platform	Estimate / Time	Notes on Production Capacity They are attempting to develop	Location	Sources
	Beijing Minhai Boitechnology Co., Ltd	Manufacturing	IV	Unknown	their own COVID vaccine, but are only in Phase I	Beijing	http://en.biominhai.com/
	Institue of Medical Biology	Manufacturing	IV		Ability to manufacture their own COVID vaccine (Phase III)	Kunming, Yunnan Province	http://english.nmpa.gov.cn/2020-06/22/c_502093.htm
	W. S.	Manufacture (their own	D.V.	Estimated capacity of 200 million doses a year, starting			https://www.reuters.com/article/uk-health-coronavirus-china-vaccine-
	Walvax Biotechnology Co.	COVID candidate)	RNA	in mid-2021		Kunming	idUKKBN2910CR https://www.edenbiologics.com/latest-news/jhl-biotech-to-develop-
	JHL biotech	Manufacture (antigen for Adimmune)	PS			Wuhan, China	and-manufacture-gmp-grade-antigen-for-taiwans-leading-covid-19- vaccine-produced-by-adimmune/
	Clover Biopharmaceuticals	Manufacturing (their own COVID candidate)	PS	1 billion doses of COVID antigen annually	Four times 2,000L single use bioreator capacity	Huzhou, Zhejiang	https://www.cloverbiopharma.com/manufacturing/
	Anhui Zhifei Loncom	Manufacturing (their own COVID candidate;					
	Biopharmaceutical	ZF2001)	PS	300 million doses per year			https://www.globaltimes.cn/page/202103/1217214.shtml http://www.mgmjms.com/article.asp?issn=2347-7946;year=2020;
	Hualan Biological Bacterin						volume=7;issue=2;spage=86;epage=96;aulast=Ghosh
Cuba	(Engineering)	Manufacture (Sputnik)	VVnr	100 million doses per year		Henan Province	https://rdif.ru/Eng_fullNews/6720/
	Center for Biotechnology and Bioengineering (CIBG),						
	coordinated by the Finlay Institute	Manufacture	PS	100 million doses a year (2021)		Havana	
Carab Barrabiia	BioCubaFarma	Manufacture (Finlay)	PS	Unknown		Havana	https://www.biocubafarma.cu/
Czech Republic	Praha Vaccines a.s. (Cyrus	Manufacture antigen	D0			B.1	https://ir.novavax.com/news-releases/news-release-details/novavax-
Denmark	Poonawalla Group)	(Novavax)	PS	1 billion doses a year		Bohumil	expands-large-scale-global-manufacturing-capacity
							https://www.agc.com/en/news/detail/1201206_2814.html
	AGC Biologics	Matrix-M adjuvant (Novavax)	PS		Three 500L mamalian bioreactors Two 1,500L microbial bioreactors	Copenhagen	https://www.fiercepharma.com/manufacturing/agc-biologics-plots- new-194-5m-building-at-copenhagen-site-to-build-global
		Manufacture					https://www.globenewswire.com/news- release/2020/07/22/2065534/0/en/Bavarian-Nordic-and-AdaptVac-
Egypt	Bavarian Nordic	(AdaptVac)	VLP / PS	Unknown		Copenhagen	Sign-Final-License-Agreement-on-COVID-19-Vaccine.html
	VACSERA	Manufacturer (Sinovac)	IV	Unknown		Giza	https://www.egypttoday.com/Article/1/95437/Egypt-to-obtain-0-5-M-COVID-19-doses-by
F	Minapharm	Manufacture (Sputnik)	VVnr	40 million a year		Cairo	https://rdif.ru/Eng_fullNews/6727/
France		Formulate, fill and					https://drug-dev.com/recipharm-announces-signature-of-letter-of-
	Recipharm AB	finish mRNA-1273 (Moderna)	RNA	Unknown		Monts, France	intent-for-aseptic-fill-finish-manufacturing-of-modernas-covid-19- vaccine-candidate/
		Large scale VV manufacture					https://www.novasep.com/home/about-novasep/media-events/press- release/novasep-opens-%E2%82%AC27m-new-viral-vector-
	Novasep	(AstraZeneca)	VVnr		Biorectors of 50 - 2,000L	Chasse-sur-Rhône	commercial-production-facility.html https://www.lefigaro.fr/societes/covid-19-quels-sont-les-sites-qui-
		E				D. (D. ()	produiront-les-vaccins-en-france-20210203
	Fareva	Fill and Finish Manufacturing (CureVac)	RNA	Millions, exact estimate unknown	Beginning May 2021	Pau (Pyrénéés- Atlantiques) and Val-de- Reuil (Eure)	https://www.curevac.com/2020/12/09/curevac-and-fareva-sign- agreement-for-fill-finish-manufacturing-of-curevacs-covid-19-vaccine- candidate-cyncov/
		Manufacturing (Pfizer-		Several tens of millions,			https://www.lefigaro.fr/societes/covid-19-quels-sont-les-sites-qui-
	Delpharm	BioNTech)	RNA	exact estimate unknown	From April 2021	Saint-Rémy-sur-Avre	produiront-les-vaccins-en-france-20210203 https://www.reuters.com/article/us-health-coronavirus-vaccines-
	Sanofi Pasteur	Fill & Flnish (Pfizer- BioNTech)	RNA	125 million doses			sanofi-idUSKBN29V23Y: https://www.sanofi.com/en/media- room/press-releases/2021/2021-01-27-07-30-00
	Sanofi Pasteur	Fill and Finish (J&J)	VVnr	144 million doses a year		Neuville sur Saône	https://www.sanofi.com/en/media-room/press-releases/2021/2021-02- 22-11-40-00-2179318
Germany				250 million doses first half of			
	BioNTech	Manufacture (Pfizer)	RNA	2021 (with Marberg facility)	500m^2 cleanroom area	Idar-Oberstein	https://www.biontech-imfs.de/en/facility/ https://www.reuters.com/article/health-coronavirus-vaccines-baxter-
	BioNTech	Manufacture (Pfizer)	RNA	750 million doses		Marberg	intl/update-1-baxter-to-start-production-in-germany-of-biontech-pfizer- vaccine-by-early-march-idUKL8N2JO32D
				250 million doses first half of 2021 (with Idar Oberstain			
	BioNTech	Manufacture (Pfizer)	RNA	factility) 125 million doses beginning		Mainz Frankfurt	https://www.sanofi.com/en/media-room/press-releases/2021/2021-01-
	Sanofi Pasteur	Manufacture (Pfizer) Fill and Finish, bulk	RNA	summer 2021			27-07-30-00
	Dermapharm	lipid supply for encapsulation (Pfizer)	RNA	Unknown	Potential bottleneck in lipid supply (see also Polymun)	Brehna	https://www.thechemicalengineer.com/news/attention-turns-to- vaccine-production-following-successful-trials-mag/
	Baxter BioPharma Solutions	Fill and Finish (Novavax)	RNA	Unknown		Halle	https://www.baxter.com/baxter-newsroom/baxter-biopharma- solutions-announces-sterile-manufacturing-agreement-novavax-covid
		,					https://www.fiercepharma.com/manufacturing/vaccine-manufacturing- greenhom-bayer-to-make-160m-doses-curevac-s-covid-19-mrna-
	Bayer	Manufacturing (CureVac)	RNA	160 million doses	Beginning 2022	Wuppertal	shot#:~:text=As%20part%20of%20a%20recently.in%20a%20press% 20briefing%20Monday.
					Capacities at Dessau site that were reserved for Takeda now		
					being used to fill and finish J&J COVID-19 vaccine. This		
	IDT Biologika	Fill & Finish (J&J)	VVnr	Unknown	agreement is only for three months.	Dessau-Rosslau	https://idt-biologika.com/idt-biologika-and-takeda-support-production- of-the-johnson-und-johnson-single-shot-covid-19-vaccine
					Vaccine manufacturer IDT Biologika will jointly invest in		
		Manufacturin			additional production capacities at its headquarters in Dessau with		https://dt biologika.com/isi-t-it-i
	IDT Biologika	Manufacturing (AstraZeneca)	VVnr	Unknown	pharmaceutical group AstraZeneca.	Dessau-Rosslau	https://idt-biologika.com/joint-investment-in-production-capacities-at-the-dessau-site
	Rentschler Biopharma	Manufacturing	DNA	100 million desse		Launhaim Correction	https://european-biotechnology.com/up-to-date/latest- news/news/rentschler-biopharma-to-produce-100m-doses-of-curevac- vaccine.html
	,	(CureVac)	RNA	100 million doses annually	5	Laupheim, Germany	https://www.rentschler-biopharma.com/news/press-releases-and-
	Rentschler Biopharma	Manufacture (Pfizer)	RNA		Downstream processes		announcements/detail/view/joining-forces-against-sars-cov-2/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-
	Cural/aa	Manufacturing	DNA	Hakaowa	English in do :-!	Tubinger F'	to-develop-next-generation-mrna-covid-19-vaccines/#:~: text=CureVac%20is%20headquartered%20in%20T%C3%BCbingen,
	CureVac	(CureVac)	RNA	Unknown	Facility in development	Tubingen, Frankfurt	Frankfurt%2C%20and%20Boston%2C%20USA. http://ir.inovio.com/news-releases/news-releases-
	Ricther-Helm BioLogics	Manufacture (Inovio)	DNA				details/2020/INOVIO-Expands-Manufacturing-of-COVID-19-DNA- Vaccine-INO-4800-With-New-Funding-from-CEPI/default.aspx
							https://www.ema.europa.eu/en/news/ema-starts-rolling-review- sputnik-v-covid-19-vaccine
		Manufacture (Sector)					https://www.augsburger-allgemeine.de/illertissen/R-Pharm-in- lllartissen.heaptract.7ulassung.des.Compa.lmnfstnffs.Snutnik.V.
	R-Pharm	Manufacture (Sputnik V)	VVnr			llertissen	Illertissen-beantragt-Žulassung-des-Corona-Impfstoffs-Sputnik-V-id59245171.html
					And the days		https://www.siegfried.ch/?rub=278&id=0
					And the drug services firm Siegfried reports in an email that it will start large-scale filling and		https://www.siegfried.cd/siegfried.cd/siegfried+and+biontech+sign+contract+for+the+aseptic+fill+% 2526+finish+of+a+covid-19+vaccine/news-en/5746
					packaging of Pfizer's vaccine in Hameln, Germany, at the		https://cen.acs.org/business/outsourcing/Pfizer-Moderna-ready-
	Siegfried	Fill and Finish (Pfizer) Lipid Nano Particles	RNA	Unknown	beginning of July 2021	Hameln Hanau	vaccine-manufacturing/98/i46 https://corporate.evonik.com/en/evonik-strengthens-strategic-
	Evonik	(Pfizer)	RNA			Dossenheim	partnership-with-biontech-on-covid-19-vaccine-152784.html

Kazakhstan	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity	Location	Sources
Kazakhstan		Manufacture					https://www.curevac.com/2021/03/30/celonic-and-curevac-announce-agreement-to-manufacture-over-100-million-doses-of-curevacs-covid-
	Celonic	(CureVac)	RNA	100 million doses		Heidelberg	19-vaccine-candidate-cvncov/
India	Karaganda	Manufacture (Sputnik V)	VVnr	2 million doses	Intended to begin production in 2021		https://www.reuters.com/article/us-health-coronavirus-vaccine- kazakhstan-idUSKBN28V12J
mula	Serum Institute of India Pvt. Ltd.	Manufacturing (AstraZeneca)	VVnr	100 million doses a month as of March 2021	Agreement to manufacture 1 billion doses	Pune	https://theconversation.com/vaccine-production-in-south-africa-how- an-industry-in-its-infancy-can-be-developed-153204
	Serum Institute of India Pvt. Ltd.	Manufacturing (Novavax)	PS	100 million doses a month as of March 2021	billott doses	i die	an-industry-in-its-intancy-can-be-developed-13220-
	Bharat Biotech International	Manufacturing				Hyderabad and other 3	https://timesofindia.indiatimes.com/india/bharat-biotech-aims-to-make-700-million-doses-of-covid-19-vaccine-in-
	Limited	(Covaxin) Manufacturing (Sputnik	IV, PS, VLP	120 million doses a year expected by july: 50 million a		facilities	2021/articleshow/80097743.cms
	Virchow Biotech	V) Manufacturing	VVnr	month			https://www.hindustantimes.com/cities/mumbai-news/haffkine-gets- maharashtra-govt-nod-94-crore-grant-for-covaxin-101619638059512.
	Haffkine Institute	(Covaxin) Manufacturing (Sputnik	IV	228 million doses a year produce a minimum of 200		Mumbai	html
	Stelis Biopharma	(V)	VVnr	million doses		Bengaluru	https://health.economictimes.indiatimes.com/news/pharma/rdif-
							hetero-to-produce-over-100-million-doses-of-sputnik-v-vaccine-in-india/79443469
	Hetero Biopharma	Manufacturing (Sputnik V)	VVnr	More than 100 million doses every year		Hyderabad	https://www.reuters.com/article/health-coronavirus-india-russia-idUSKBN28S0XL
	Biological E Ltd.	Manufacturing (J&J) Manufacturing	VVnr, PS	600 million doses a year		Hyberabad	https://www.reuters.com/article/idUSKBN2AA0IV
		(Moderna), on-going talks as of January					https://theprint.in/health/vaccine-maker-iil-other-companies-in-touch-
	Indian Immunologicals	2021 Manufacturing	RNA	Unknown		Hyderabad	with-moderna-to-bring-its-covid-vaccine-to-india/582889/
	Indian Immunologicals	(Covaxin)	IV	400 - 111 - 4 - 4 - 4 - 4		Hyderabad	https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1712271 https://www.contractpharma.com/contents/view_online-
	Dr Reddy's Laboratories CPL biologicals Pvt. Ltd (a	Manufacturing (Sputnik V)	VVnr	100 million doses (unknown time frame)		Hyderabad	exclusives/2020-10-20/india-emerges-as-hot-spot-for-manufacturing- covid-19-vaccines/ https://www.fiercebiotech.com/biotech/novavax-and-cpl-biologicals-
	joint venture of Cadila Pharmaceuticals and	Manufacturing	VLP & IV (cell based)	60 million dosses per year		Ahmadahad	break-ground-on-new-influenza-vaccine-manufacturing-facility#:~: text=The%20CPL%20Biologicals%20facility%20is.on%
	Novavax)	(Novavax) Manufacturing (nCov	,	60 million doses per year		Ahmedabad	20Novavax's%20VLP%20vaccine%20technology. https://www.businesstoday.in/current/corporate/zydus-cadila-covid-vaccine-to-be-ready-by-march-second-vaccine-under-
	Cadila Healthcare Limited	vaccine)	DNA	100 million doses per year		Ahmedabad Two locations:	development/story/419971.html https://www.reuters.com/article/health-coronavirus-panacea-
	Panacea Biotec Ltd	Manufacturing (unamed vaccine)	LAV, VLP & PS	500 million doses early 2021 1 billion doses in 2022		District Solan District Mohali	biotec/panacea-biotec-aims-to-make-1-billion-doses-of-covid-19- vaccine-candidate-in-2022-idINKBN2491BL?edition-redirect=in
	Panacea Biotec Ltd	Manufacturing (Sputnik)	VVnr	100 million doses a year			https://rdif.ru/Eng_fullNews/6688/
	Verity Pharmaceuticals	Manufacturing / Distributing (AstraZeneca)	VVnr				https://www.reuters.com/article/us-health-coronavirus-canada- vaccine-idUSKBN2A21JU
	Gland Pharma	Manufacture (Sputnik	VVnr	252 million doses		Hydorobod	https://www.reuters.com/article/health-coronavirus-russia-vaccine- india/indias-gland-pharma-to-make-up-to-252-million-sputnik-v-
	Gland Pharma	(V)	vvnr	252 million doses		Hyderabad	vaccine-doses-idUSKBN2B812S https://economictimes.indiatimes.
	Hester Biosciences	Manufacturing (Covaxin)	IV		from August 2021	Gujarat	com/industry/healthcare/biotech/pharmaceuticals/pact-signed- between-bharat-biotech-gujarat-covid-vaccine-consortium-hester- biosciences/articleshow/83012906.cms?from=mdr
	Shilpa Biologics	Manufacture (Sputnik V)	VVnr	100 - 200 million doses			https://www.reuters.com/article/us-health-coronavirus-india-vaccine- idUSKBN2BU00G
Indonesia							https://www.japantimes.co.jp/news/2020/11/27/asia-pacific/covid-19-
		Manufacturing (Merah					vaccine-indonesia/ https://www.universityworldnews.com/post.php?
	Bio Farma	Putih)	PS	Unknown		Bandung	story=20200915121452749 https://www.reuters.com/article/us-health-coronavirus-indonesia-
		Manufacturing		16 - 17 million doses per			idUSKBN29G0RP https://www.abc.net.au/news/2021-01-13/indonesia-starts-rolling-out-
Iran	Bio Farma	(Sinovac)	IV	month		Bandung	jabs-of-chinas-covid-19-vaccine/13051430
	Shifa Pharmed	Manufacture (their own COVID vaccine)	IV	12 million doses a month (if trial successful)		Tehran	https://www.reuters.com/article/us-health-coronavirus-iran-vaccine- idUSKBN2930RE
							https://www.pmewswire.com/news-releases/rdif-celebro-una-reunion- del-consejo-internacional-de-expertos-con-la-participacion-del- presidente-ruso-vladimir-putin-con-ocasion-del-spief-2021-
Israel	Cinnagen	Manufacture (Sputnik)	VVnr				855796995.html
ioraci							https://www.timesofisrael.com/israel-begins-mass-producing- coronavirus-vaccines-ahead-of-human-trials/
	Israel Institute for Biological Research	Manufacturing	VVnr	15 million doses estimated ready by July 2021		Ness Ziona, Israel	https://www.timesofisrael.com/israeli-vaccine-clears-first-stage-as-no- maior-side-effects-reported/
Italy	Research	Ivianuracturing	VVIII	ready by July 2021		INESS ZIUIIA, ISIAEI	
	Catalent, Inc	Fill and Finish (J&J)	VVnr	Unknown		Anagni, Italy	https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine- supply-chain-stability-eyes-plans-for-2022
				Hundreds of millions of			https://www.catalent.com/catalent-news/catalent-signs-agreement- with-astrazeneca-to-manufacture-covid-19-vaccine-candidate/
	Catalent Inc.	Manufacture (AstraZeneca)	VVnr	doses between August 2020 and March 2022		Anagni, Italy	https://www.fiercepharma.com/manufacturing/catalent-pumps-50m- into-indiana-fill-finish-capacity-covid-19-vaccine-contracts-hand
				16 million doses in first 3			https://www.reuters.com/article/uk-health-coronavirus-italy-vac:/ne/italy-set-for-16-million-astrazeneca-covid-19-shots-in-early- 2021-source-idUKKBN2841KY; https://www.advent-gmp.
	IDDM	Manufacture	\0/or	months of 2021			com/news/irbms-advent-announces-manufacture-of-13000-doses-of- covid-19-vaccine-for-use-in-phase-2-3-clinical-trials-by-the-university-
	IRBM	(AstraZeneca)	VVnr	70 million Aiming to produce 100			of-oxford/ https://www.ansa.it/english/news/general_news/2021/01/05/new- reithera-vaccine-safe-response-peak-at-4-wks_a2f0ac15-22f5-4c79-
	ReiThera	Manufacturing	VVnr	million doses per year		Castel Romano, Rome	Telinera-vaccine-sate-response-peak-at-4-wks_aztuac15-22t5-4c79- 9501-b55161d50352.html https://tass.com/economy/1263597
	Adienne Pharma & Biotech	Manufacture (Sputnik V)	VVnr	Beginning in June producing 10 million in 2021		Caponago MB	https://www.swissinfo.ch/eng/swiss-based-pharma-group-to-produce-sputnik-vaccine-in-italy/46433126
1	Biotech SA	Manufacture (Sputnik V)	VVnr				https://tass.com/economy/1263597
							https://www.pmewswire.com/news-releases/rdif-celebro-una-reunion-del-consejo-internacional-de-expertos-con-la-participacion-del-
		Manufacture (Sputnik	VVnr				presidente-ruso-vladimir-putin-con-ocasion-del-spief-2021- 855796995.html
	Avara Liscate	(V)	VVIII				
		Manufacture (Agnes		1 million doses by March 2021		Kusatsu	https://asia.nikkei.com/Spotlight/Coronavirus/Japan-to-ready-1m-doses-of-coronavirus-vaccine-for-swift-distribution
	Takara Bio	Manufacture (Agnes and Osaka University) Manufacture	DNA	Approx. 250 million doses a	Establishing capability to	Kusatsu	doses-of-coronavirus-vaccine-for-swift-distribution https://www.takeda.com/newsroom/newsreleases/2020/takeda- expands-covid-19-vaccine-supply-in-japan-throughpartnership-with-
		Manufacture (Agnes and Osaka University)		2021	Establishing capability to manufacture Novavax in Japan	Kusatsu	doses-of-coronavirus-vaccine-for-swift-distribution https://www.takeda.com/newsroom/newsreleases/2020/takeda-

				Production Quantity			
Country	Company	Function	Vaccine Platform	Estimate / Time	Notes on Production Capacity	Location	Sources
	ACC Bisland	Manufacture (Osaka	DNA	l laterana		Televe	https://www.agc.com/en/news/detail/1200775_2814.html#:~; text=Tokyo%2C%20May%2021%2C%202020%E2%80%93.COVID% 2D19%20DNA%20vaccine%20intermediate
	AGC Biologics	University)	DNA	Unknown		Tokyo Takasago	https://www.reuters.com/article/us-health-coronavirus-inovio-pharma-
	Kaneka Corp	Manufacture (Inovio) Manufacturing (UMN	DNA	Unknown		Osaka	idUSKBN28D1ZF
	Unigen Inc.	Pharma Vaccine)	PS	00 million doses beginning		Akita	https://www.shionogi.com/global/en/news/2020/06/e_200619.html
	Nipro Corporation	Manufacture (AstraZeneca)	VVnr	90 million doses, beginning June 2021	From June 2021	Osaka	https://www.nipro.co.jp/en/news/document/210526.pdf
		Manufacture					https://www.reuters.com/article/us-health-coronavirus-japan- vaccine/japans-km-biologics-begins-clinical-trial-of-covid-19-vaccine-
Kazakhstan	KM Biologics	(AstraZeneca)	VVnr			Kumomato Perfecture	candidate-idUSKBN2BE0YY
- Tuzukiiotuii							https://tass.com/economy/1237699
	Karaganda Pharmaceutical	Manufacturing (Sputnik V)	VVnr	Around 2 million doses per			https://www.ruptly.tv/en/videos/20201221-017-Kazakhstan
	Enterprises Research Institute for		VVIII	year			Production-of-Russia-s-Sputnik-V-vaccine-begins-in-Karaganda
	Biological Safety Problems (RIBSP)	Manufacturing (Qaz- Covid-In vaccine)	IV	Unknown		Gvardeisky	https://astanatimes.com/2020/12/kazakhstan-begins-vaccinating- 3000-volunteers-with-self-made-qazcovid-in/
Lebanon							
	Arwan Pharmaceutical Industries	Manufacturing (Sputnik)	VVnr				https://tass.com/economy/1296181
Malaysia		Manufacture, fill and		12 million doses beginning			https://www.reuters.com/article/health-coronavirus-malaysia-
	Pharmaniaga Berhad	finish (Sinovac)	IV	April 2021			<u>idCNL1N2J0009</u>
	Duopharma (M) Sdn Bhd	Manufacturing (Sputnik V)	VVnr	6.4 million doses, beginning end of March			https://www.malaymail.com/news/malaysia/2021/01/26/health- ministry-malaysia-secures-18.4-million-doses-of-russian-chinese- covi/1944232
Mexico	Duophania (W) Sun Bilu	V)	VVIII	end of March			COVI 1944232
				685,000 daily doses			https://mexico-now.com/685000-daily-vaccines-against-covid-19-will-be-packaged-in-mexico/
	Laboratorios Liomont	Fill and Finish		250 million doses in 2021(in conjunction with the facility in	In conjunction with manufacturing facility in Argentina to supply all of	Ocoyoacac, State of	https://www.mabxience.com/mabxience-enters-into-an-agreement-
	(mAbxience of INSUD Group)	(AstraZeneca)	VVnr	Argentina)	Latin America (except Brazil)	Mexico	with-astrazeneca-to-produce-covid-19-vaccine/
		Manufacture (C. 1."					https://www.fdanews.com/articles/198943-landsteiner-scientific-to- distribute-russias-covid-19-vaccine-in-mexico; https://www.
	Landsteiner Pharmaceutical	Manufacture (Sputnik V)	VVnr				theyucatantimes.com/2020/09/ministry-of-health-denies-arrival-of- sputnik-v-vaccine-in-mexico/
	Drugmex	Fill & Finish (CanSino)	VVnr			Querétaro	https://www.gob.mx/sre/prensa/the-first-covid-19-vaccines-packaged-in-mexico-leave-the-drugmex-plant
Pakistan							
		Manufacture (Sputnik					https://www.reuters.com/article/us-health-coronavirus-pakistan- yaccine/pakistan-lab-expects-sputnik-v-doses-for-commercial-sale-in-
	Ali Gohar Pharmaceuticals	(V)	VVnr				a-week-idUSKBN2AE06D https://www.bloomberg.com/news/articles/2021-01-22/china-vaccine-
	AJM Pharma Pvt	Manufacture (CanSino) Fill and Finish	VVnr	20 million			maker_cansino-to-offer-pakistan-20-million-doses https://www.brecorder.com/news/40076698/pakistan-soon-to-start-
	National Institute of Health	(CanSino)	VVnr	200,000 doses in May 2021			manufacturing-covid-vaccine-by-using-technology-transfer-from-china
	Searle Company Limited	Manufacture (Livzon Mapharm V-01)				Islamabad	https://www.arabnews.pk/node/1836216/pakistan
Philippines		Manufacture					
	Glovax Biotech	(EuCorVac-19)	PS	Unknown			https://www.pna.gov.ph/articles/1132120
Poland							https://www.reuters.com/business/healthcare-
	Mabion SA	Manufacture (Novavax)	PS				pharmaceuticals/poland-strikes-deal-produce-novavax-covid-19- vaccine-2021-03-03/
Republic of South Korea		,					
Korea		Manufacturer					
	GC Pharma	(partnered with CEPI) Manufacturing (Sputnik	PS	500 million doses a year More than 150 million doses		Seoul	https://www.reuters.com/article/health-coronavirus-russia-vaccine-
	GL Rapha	V) Manufacturing antigen	VVnr	per year	40 million for South Korea, and	Seoul	idlNKBN27T0KO https://ir.novavax.com/news-releases/news-release-details/novavax-
	SK Bioscience	(Novavax)	PS	Unknown	more for global supply	Andong	and-sk-bioscience-announce-collaboration-novavax-covid
	SK Bioscience	Manufacturer (AstraZeneca)	VVnr	Unknown		Andong	https://fr.yna.co.kr/view/AFR20201118001100884
	LG Chem	Manufacturing (Cellid)	VVnr			Seoul	https://www.koreabiomed.com/news/articleView.html?idxno=9876 https://www.reuters.com/business/healthcare-
	Huons Global Co Ltd	Manufacture (Sputnik)	VVnr	100 million doses a year			pharmaceuticals/skorean-consortium-produce-100-mln-doses-month- russias-sputnik-v-vaccine-2021-04-16/
	Fidoris Global Co Eta	iviariaracture (oputrik)	V V I I	Too million doses a year			https://investors.modernatx.com/news-releases/news-release-
							details/moderna-and-samsung-biologics-announce-agreement-fill- finish
		Fill and finish			Begin production third quarter of		https://www.fiercepharma.com/pharma/samsung-adds-mma-vaccine-
	Samsung Biologics	(Moderna)	RNA	500 million doses	2021	Incheon	substance-capacity-will-have-one-stop-site-for-manufacture-moderna https://www.reuters.com/article/health-coronavirus-southkorea-
	Hanmi Pharm	Manufacture (Genexin)	DNA				vaccine/skoreas-genexine-signs-covid-19-vaccine-candidate- manufacturing-deal-with-hanmi-idUSL3N2N50XZ
Russia		, , , , , , , , , , , , , , , , , , , ,					
		Manufacturing (Sputnik					https://www.firstpost.com/tech/science/russias-covid-19-vaccine-to-enter-production-deliver-first-batch-of-doses-in-two-weeks-8700091.
	Binnopharm	(V)	VVnr	500 million doses a year 20 million doses a month		Moscow	https://www.cleanroomtechnology.
	R-Pharm	Manufacturing (Sputnik V)	VVnr	(when factory reaches full capacity)		Yaroslavl	com/news/article_page/Wiskind_assists_Moscow_R- Pharm to build_Covid-19_vaccine_plant/173321
	R-Pharm	Manufacturing (AstraZeneca)	VVnr	Unknown		Moscow	https://www.reuters.com/article/health-coronavirus-cyber-russia-
	R-Pharm (SEZ Technopolis	Manufacturing (Sputnik					vaccine-idINKCN24I1X9
	Moscow)	(V)	VVnr	Unknown 1 million doses of Sputnik in		Moscow, Pechatniki	
	BIOCAD Company	Manufacturing (Sputnik V)	VVnr	December 2020 + 3-4 million doses per month		St Petersburg	https://tass.com/society/1225549
	a an pany						https://www.bnnbloomberg.ca/russia-s-richest-man-seeks-global-
	Petrovay	Manufacture (CCi	Wynr			Moscow	market-for-local-covid-19-drug-1.1527470 ; https://petrovax.com/press_centre/news/2020/1881/
	Petrovax	Manufacture (CanSino)				Moscow	https://pharmasyntez.com/en/press-center/news/pharmasyntez-will-
	Pharmasyntez	Manufacture (Sputnik) Manufacture (Covi-	VVnr			St Petersburg	produce-the-covid-19-sputnik-v-vaccine/?sphrase_id=15954 https://www.reuters.com/article/us-health-coronavirus-russia-vaccine-
Carbia	Chumakov	Vac)	IV	500,000 doses a month			idUSKBN2AK07H
Serbia		Manufacturing (Sputnik		60 - 100 million vaccine			https://www.osw.waw.pl/en/publikacje/analyses/2020-11-26/russian-
	Generium	V)	VVnr	doses a year		Vladimir Region, Serbia	vaccines-a-production-bottleneck
	Torlak	Manufacture (Sinopharm)	IV				https://balkaninsight.com/2021/03/12/serbia-unveils-plan-to-produce- chinese-vaccine-jointly-with-uae/
South Africa							https://www.aspenpharma.com/2020/11/02/aspen-announces-
							agreement-with-johnson-johnson-to-manufacture-investigational- covid-19-vaccine-candidate/
							https://www.aspenpharma.com/2020/11/02/aspen-announces-
	Pharmacare Limited (Aspen Pharmacare)	Fill and Finish (J&J)	VVnr	More than 300 million doses		Located in Port Elizabeth, South Africa	agreement-with-johnson-johnson-to-manufacture-investigational-
	rnamacare)	riii anu rinish (J&J)	v viil	per year	1	Enzabeth, South Africa	covid-19-vaccine-candidate/

				Production Quantity			
Country	Company	Function	Vaccine Platform	Estimate / Time	Notes on Production Capacity	Location	Sources
					Currently distributing the		
					AstraZeneca vaccine.		https://www.biovac.co.za/manufacturing/
					Will collaborate with ImmunityBio to manufacture second generation		https://www.timeslive.co.za/sunday-times/news/2021-02-07-a-home-grown-covid-19-vaccine-deal-is-near-says-biovac-ceo/
	B	Fill and Finish and some manufacturing	104	Up to 30 million doses per	COVID-19 vaccine	0	https://www.timeslive.co.za/news/south-africa/2021-03-18-cape-town
	Biovac Institute	(ImmunityBio)	VVnr	year	mRNA manufacturing hub	Cape Town	company-to-manufacture-covid-19-vaccine/
							https://www.who.int/news/item/21-06-2021-who-supporting-south-
	Afrigen Biologics and Vaccines	Manufacturing	RNA		will be part of Africa's mRNA manufacturing hub		african-consortium-to-establish-first-covid-mma-vaccine-technology- transfer-hub
Spain	Vaccines	iviaridiacturing	INIX		manufacturing nub		
							https://www.reuters.com/article/us-health-coronavirus- moderna/moderna-signs-deal-with-spains-rovi-to-supply-potential-
							covid-19-vaccine-outside-u-s-idUSKBN24A1SV
	Laboratorios Farmaceuticos Rovi	Fill and Finish (Moderna)	RNA	120 million syringes to 300 million units			https://www.fiercepharma.com/special-report/top-10-manufacturers- fight-against-covid-19-rovi
				Reserved capacity of 500			https://www.pharmamanufacturing.com/industrynews/2020/novavax- doubles-covid-vax-manufacturing-capacity/
		Manufact		million doses for CEPI			https://zendal.com/en/biofabri-of-zendal-group-has-been-selected-by-
	Biofabri	Manufacture (Novavax)	PS	Unclear how many doses estimated for Novavax			the-cepi-as-a-strategic-facility-to-increase-the-manufacturing- capacity-of-covid-19-vaccines-at-an-international-scale/
		Manufacturing	106	000	0.0001 5		https://www.mabxience.com/spanish-group-insud-pharma-signs- agreement-with-astrazeneca-to-manufacture-covid-19-vaccine-
	mAbxience	(AstraZeneca)	VVnr	200 million a year	2,000L lines	Léon	candidate/ https://www.reigjofre.com/en/noticias/item/reig-jofre-announces-
	Reig Jofre	Manufacture (J&J)	VVnr	50 million a year			technology-transfer-of-the-large-scale-manufacturing-in-spain-for-a- covid-19-vaccine-candidate/
Sweden		Matrix-M adjuvant					https://www.pharmamanufacturing.com/industrynews/2020/novavax-
	Novavax AB	(Novavax)	PS	Unknown	6,000L total reactor capacity for	Uppsala	doubles-covid-vax-manufacturing-capacity/
	PolyPeptide Group	Intermediary used in Matrix-M (Novavax)	PS	Unknown	solution phase 600L capacity for solid phase		https://www.pharmamanufacturing.com/industrynews/2020/novavax-doubles-covid-vax-manufacturing-capacity/
Switzerland	. ciyi opudo ordap	maux m (norarax)		O THE I CHILD	coor capacity for cona priace		
							https://www.bloomberg.com/news/articles/2020-11-19/moderna- vaccine-production-is-gearing-up-partner-lonza-says
		Manufacturing					https://www.reuters.com/article/us-health-coronavirus-lonza-moderna
	Lonza Group AG	ingredients (Moderna)	RNA	300 million doses		Visp Stein am Rhein	idUSKBN29G26L https://www.pharmiweb.com/pwtoday-story/novartis-signs-initial-
	Novartis	Manufacturing (Pfizer)	RNA	Unknown	First shippment expected to be released in third quarter of 2021	Supporting production of Pfizer-BioNTech	agreement-to-provide-manufacturing-capacity-for-pfizer-biontech- covid-19-vaccine
Thailand		Manufacturing					https://www.voanews.com/covid-19-pandemic/thai-firm-joins-
	Siam Bioscience	(AstraZeneca)	VVnr	200 million doses		Bangkok	astrazeneca-make-covid-19-vaccine-southeast-asia
Taiwan							http://www.adimmune.com.tw/en/news_content.php?id=161
		Manufacture and					http://www.jhlbiotech.com/latest-news/jhl-biotech-to-develop-and-
	Adimmune Corporation	supply antigen for COVID vaccine	PS	Unknown	Two sterile filling lines		manufacture-gmp-grade-antigen-for-taiwans-leading-covid-19- vaccine-produced-by-adimmune/
	TTY Biopharm Copmany	Manufacture (Pfizer)	RNA				https://focustaiwan.tw/sci-tech/202011100025; https://fr.rti.org. tw/news/view/id/92973
	Medigen Vaccine Biologics Co.	Manufacturing	PS	20 million doses in 2021	Ability to manufacture their own COVID vaccine (Phase II)		https://www.taipeitimes. com/News/biz/archives/2020/11/04/2003746299
The Netherlands		Manufacturing					https://www.reuters.com/article/us-health-coronavirus-halix-
	HALIX B.V.	(AstraZeneca)	VVnr	Unknown		Leiden	astrazeneca-idUSKBN28I24E
							https://www.fiercepharma.com/manufacturing/curevac-ties-up- wacker-to-churn-out-more-than-100m-doses-mrna-coronavirus- vaccine
		Manufacturing					https://www.wacker.com/cms/en-us/about-wacker/press-and-
	Wacker Chemie	(CureVac)	RNA	100 million doses in 2021	Unclear whether AZ COVID	Amsterdam	media/press/press-releases/detail-150656.html
	MedImmune Pharma B.V. (subsidiary recently renamed Astra Zeneca)	Manufacturing (biologics)		Unknown	vaccine will be manufactured at this site	Nijmegen	
						,	https://bioconnection.eu/news/adaptvac-partners-with-bioconnection- to-manufacture-their-covid-19-vaccine/
		Manufacturing (AdaptVac)			Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine		to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-
	BioConnection BV	Fill and Finish	PS	200-500 million doses	production	Oss	the-way-in-the-med-tech-and-e-health-field/
	Janssen	Manufacturing (J&J)	VVnr	300 million doses a year		Leiden	https://bioprocessintl.com/bioprocess-insider/global-markets/ijs-covid 19-vaccine-four-production-plants-one-billion-doses-by-end-of-2021/
		Manufacturing	DNA	200:		Calana	https://www.politico.eu/article/moderna-to-double-eu-vaccine- manufacturing-with-new-dutch-site/?
Turkey	Lonza	(Moderna)	RNA	300 million doses a year		Geleen	utm_medium=Social&utm_source=Twitter#Echobox=1622619513
	VisCoran Ilac Sanayii A.S.	Manufacture (Sputnik V)	VVnr	Unknown			https://www.bloomberg.com/news/articles/2021-02-03/secretive- russia-deal-allows-erdogan-ally-to-produce-sputnik-v
							https://www.pmewswire.com/news-releases/rdif-celebro-una-reunion- del-consejo-internacional-de-expertos-con-la-participacion-del-
	Cinnagen	Manufacture (Sputnik V)	VVnr				presidente-ruso-vladimir-putin-con-ocasion-del-spief-2021- 855796995.html
United Arab Emirates	,						
							https://www.reuters.com/article/us-health-coronavirus-emirates-china idUSKBN2BJ0H3
	Gulf Pharmaceutical	Manufacture					https://www.bloomberg.com/news/articles/2021-03-28/julphar-signs-
Haitad King to	Industries PSC (Group 42)	(Sinopharm)	IV	2 million doses a month		Ras al-Khaimah	deal-with-abu-dhabi-firm-to-produce-sinopharm-shot
United Kingdom		Lipid-based excipients				Cowick Hall, Snaith	
	Croda Polymer Additives	(Pfizer) Fill and Finish	RNA	Unknown		Goole	https://www.business-live.co.uk/manufacturing/uk-factories-making-
	CP Pharmaceuticals	(AstraZeneca)	VVnr	300 million doses a year		Wrexham	astrazeneca-vaccine-19708380
	FUJIFILM Diosynth Biotechnologies	Manufacturing - antigens (Novavax)	PS	About 180 million doses annually		Billingham, Stochton-on- Tees	https://fujifilmdiosynth.com/about-us/press-releases/novavax-and-uk- government-announce-collaboration-and-purchase-agreement-for- novavax-covid-19-vaccine-candidate/
		ngono (reordvax)	-	Up to 60 million jabs			DESCRIPTION OF THE PROPERTY OF
				manufactured by the end of 2021 Further 130 million doses if			
	Valneva	Manufacturing (Valneva +NIH)	IV	proven to be safe and effective		Livingston, West Lothian, Scotland	https://www.gov.uk/government/news/large-scale-coronavirus-
	vallicva	(vallicva +INIH)	I V	enective	1	Lounan, Scottand	vaccine-manufacturing-begins-in-scotland

			T	In the contract of the contrac	I		
Country	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity	Location	Sources
					Four dedicated suites for viral vector production		
	0 (5 6				Two suits for fill and finish		
	Oxford Biomedica (Oxbox production plant)	Manufacturing viral vectors (AstraZeneca)	VVnr	Unknown	1,000L of reserved capacity for AstraZeneca	Oxfordshire	https://www.fiercepharma.com/manufacturing/oxford-biomedica- earns-uk-nod-for-4th-manufacturing-suite-to-boost-covid-19
	Cabas Bislasias	Manufacturing (AstraZeneca)	10/	4		Kaala I laissaaits	https://www.reuters.com/article/health-coronavirus-vaccine-cobra-
	Cobra Biologics	Manufacturing	VVnr	1 million doses a month Up to 100 million doses in	Unicear what GSK sites will be	Keele University	biologi-idUSL8N2DT1YB https://www.fiercepharma.com/pharma/gsk-amid-sanofi-delay-teams
	GlaxoSmithKline (GSK)	(CureVac)	RNA	2021	manufacturing CureVac		curevac-multivalent-covid-19-vaccine-to-tackle-variants
	GlaxoSmithKline (GSK)	Fill & Finish (Novavax) Fill and Finish (partially	PS	60 million doses	Beginning as early as May 2021 One line dedicated to	Barnard Castle	https://www.ft.com/content/55f1776f-84bb-45bd-83cc-bdc825817879 https://www.fiercepharma.com/manufacturing/az-taps-indian-pharma
	Wockhardt	for AstraZeneca)	VVnr	Up to 240 million doses	AstraZeneca	Wrexham, North Wales	wockhardt-for-u-k-shot-finishing
United States							
							https://www.wbaltv.com/article/covid-19-vaccine-johnson-and- johnson-to-be-made-in-baltimore-emergent-biosolutions/35354774#
							. https://www.reuters.com/article/uk-health-coronavirus-johnson-
	Emergent BioSolutions	Manufacturing (J&J)	VVnr	More than 1 billion doses		Baltimore	johnson-idUKKCN2253U4
	Exelead	Manufacturing (Pfizer) - lipid nanoparticles	RNA			Indianapolis	https://www.exeleadbiopharma.com/news/exelead-helps- manufacture-pfizer-biontech-covid-19-vaccine
	Emergent BioSolutions	Clinical test quantities (Novavax)	PS			Baltimore	https://www.contractpharma.com/content-microsite/covid-19/2020-0
	Emergent bioSolutions	(NOVAVAX)	P5			Gaithersburg, Mayland	10/emergent-biosolutions-novavax-enter-covid-19-pact https://investors.emergentbiosolutions.com/news-releases/news-
	Emergent BioSolutions	Manufacturing (AstraZeneca)	VVnr		Agreement worth \$174 million	Baltimore Winnipeg, Canada	release-details/emergent-biosolutions-signs-agreement-astrazeneca
	Emergent biocolutions	(Astrazerieca)	V V I II		Agreement worth \$174 million	wiinipeg, canada	https://www.prnewswire.com/news-releases/gram-partners-with-
							johnsonjohnson-on-manufacturing-in-fight-against-covid-19- 301137966.html
	Grand River Aseptic	Manufacturing, Fill and					https://www.fiercepharma.com/manufacturing/johnson-johnson-signs
	Manufacturing	Finish (J&J)	VVnr	Up to 100 million doses		Grand Rapids, MI	michigan-s-grand-river-to-help-covid-19-vaccine-finishing-work
							https://www.fiercepharma.com/manufacturing/catalent-pumps-50m- into-indiana-fill-finish-capacity-covid-19-vaccine-contracts-hand
							https://www.npr.org/sections/health-
							shots/2020/12/17/947628608/how-will-moderna-meet-the-demand-
							for-its-covid-19-vaccine
	Catalent, Inc.	Fill and Finish (J&J)	VVnr	80 million additional vials per vear		Bloomington, Indiana	https://www.bloomberg.com/news/articles/2021-03-23/j-j-partner- catalent-gets-key-u-s-approval-to-make-yaccine
	Catalent, Inc.	Till and Tillian (000)	V V I II	year		Bloomington, malana	https://investor.catalent.com/financial-news/news-
		Fill and Finish		100 million initial doses			details/2020/Moderna-and-Catalent-Announce-Collaboration-for-Fill- Finish-Manufacturing-of-Modernas-COVID-19-Vaccine-
	Catalent, Inc.	(Moderna)	RNA	180 million total		Bloomington, Indiana	Candidate/default.aspx
		Manufacture viral				Harmans/BWI,	https://www.catalent.com/catalent-news/catalent-signs-agreement- with-astrazeneca-to-expand-manufacturing-support-for-covid-19-
	Catalent, Inc.	vector (AstraZeneca)	VVnr	Unknown		Baltimore	vaccine-azd1222/
		Manufacturing					https://www.catalent.com/catalent-news/arcturus-therapeutics-and- catalent-announce-partnership-to-manufacture-mrna-based-covid-1
	Catalent, Inc.	(Arcturus)	RNA	Unknown 100 million doses by the end		Madison, Wisconsin	vaccine/
	Direct	Incubates DNA to	RNA	of 2020 and 1.3 billion by		Andover, Massachuzetts	
	Pfizer	make mRNA (Pfizer)	KINA	2021		wassacriuzetts	https://www.independent.co.uk/news/world/americas/where-covid-
		mRNA-containing lipid nanoparticles					vaccine-made-portage-michigan-pfizer-b1766619.html
		constructed and					https://www.pfizer.com/products/pfizer-global-supply/us-
		sterilised (Pfizer)		100 million doses between	Expected to produce 132 million		manufacturing-sites/kalamazoo
	Pfizer	Manufacturing, fill & finish	RNA	Kalamazoo and Puurs, Belgium by the end of 2020	doses a month starting March 2021	Kalamazoo, Michigan	https://www.wsj.com/articles/covid-19-vaccine-manufacturing-in-u-s- races-ahead-11616328001
							https://www.pfizer.com/science/research-
							development/centers/mo_st_louis https://www.bizjournals.com/stlouis/news/2020/11/09/pfizer-covid-
		Plasmids for vaccine					vaccine-chesterfield-st-louis.html According to Pfizer, the local plant is the primary site of raw material
	Pfizer	(Pfizer)	RNA	Unknown	Unknown	St. Louis, Missouri	production for the vaccine, producing plasmids
	Pfizer	Fill and Finish	RNA		14 milloion sq ft.	Rocky Mount, North Carolina	https://www.pfizer.com/products/pfizer-global-supply/us- manufacturing-sites/rocky-mount
	CordenPharma	Lipid supply for mRNA	RNA			Boulder, Colorada	
	CordenPharma	(Moderna)	KINA			Boulder, Colorada	https://www.npr.org/sections/health-
	Catalent, Inc.	Manufacturing (Moderna)	RNA			Houston and Madison	shots/2020/12/17/947628608/how-will-moderna-meet-the-demand- for-its-covid-19-vaccine
	Catalent, Inc.	Manufacturing				Portsmouth, New	https://www.bloomberg.com/news/articles/2020-11-19/moderna-
	Lonza Group AG	(Moderna)	RNA	100 million doses		Hampshire	vaccine-production-is-gearing-up-partner-lonza-says
	Endo International	Manufacture & Fill and Finish (Novavax)	PS				https://investor.endo.com/news-releases/news-release-details/endo- announces-fill-finish-manufacturing-and-services-agreement
							https://www.pharmamanufacturing.com/industrynews/2020/novavax doubles-covid-vax-manufacturing-capacity/
		Intermediary used in		Enough of the adjuvant component for billions of	Enough of the adjuvant		https://asia.nikkei.com/Business/Pharmaceuticals/Japan-s-AGC-to-
	AGC Biologics	Matrix-M (Novavax)	PS	doses in 2020 ans 2021	2020 ans 2021	Seattle	expand-vaccine-agent-production-for-Novavax
							https://www.pharmamanufacturing.com/industrynews/2020/novavax.doubles-covid-vax-manufacturing-capacity/.
							https://www.fujifilm.eu/eu/news/article/fujifilm-diosynth- biotechnologies-stands-ready-to-manufacture-lilly-covid-19-antibody
							<u>for-low-and-m</u>
							https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth- biotechnologies-begins-production-of-two-covid-19-vaccines-
							candidates-at-texas-facility/
	ELLIEUM BY				6 x 20,000L bioreactors		Fujifilm is subcontractor of Texas A&M University System Center for
	FUJIFILM Diosynth Biotechnologies	Manufacturing (Novavax)	PS	Uknown	14 x 2,000L cell culture trains	North Carolina and Texas	Innovation in Advanced Development & Manufacturing (CIADM), where CIADM contract is with BARDA.
	Albany Molecular Research Inc	Manufacturing (AstraZeneca)	VVnr	Millions of doses annually (unclear in what time frame)		Albuquerque, New Mexico	https://www.reuters.com/article/uk-health-coronavirus-astrazeneca- amri-idUKKBN25U24K
		Manufacturer		(dicieal in what time frame)			https://ipolitics.ca/2020/12/08/sanofi-wont-use-its-canadian-facility-to-
	Medicago	(Medicago) Manufacturer	VLP	-		Durham, North Carolina	make-a-covid-vaccine/
		(Moderna - clinical	<u></u>			L	https://www.npr.org/sections/health- shots/2020/12/17/947628608/how-will-moderna-meet-the-demand-
	Moderna	scale facility)	RNA			Norwood, Mass	for-its-covid-19-vaccine https://www.recipharm.com/press/recipharm-announces-signature-
	B. data	Fill and Finish	544				letter-intent-aseptic-fill-finish-manufacturing-moderna%E2%80%99s
	Recipharm	(Moderna)	RNA	+	New 'virotherapy' facility set to		covid
					come online in the second half of 2021. 2,000L bioreactor capacity		https://www.fiercepharma.com/manufacturing/new-ceo-board-
	Vibalogics	Manufacturing (J&J)	VVnr	Unknown	2021. 2,000L bioreactor capacity	Near Boston	germany-s-vibalogics-lays-out-150m-for-boston-viral-vector-site
							https://manufacturingchemist. com/news/article_page/Biotech_chooses_PolyPeptide_Group_for_v
							ccine adjuvant intermediates/166644
	PolyPeptide Group	Matrix-M components (Novavax)	PS	Unknown		San Diego and Torrance, California	https://www.polypeptide.com/contact-quotation-request/facilities/sandiego-and-torrance-usa/
		Manufacturing			Linknown		https://www.cbsnews.com/amp/news/coronavirus-vaccine- astrazeneca-ramping-up-production/
	Pall (subsidiary of Danaher)	(AstraZeneca)	VVnr	Unknown	Unknown	Port Washington, NY Austin, TX (Thermo	astrazeneca-ramping-up-production/
						Fisher HQ here -	http://ir.inovio.com/news-releases/news-releases-
	Thermo Fisher Scientific	Manufacturing (Inovio)	DNA	100 million annually	Unknown	specific site of manufacture unclear)	details/2020/INOVIO-Adds-Thermo-Fisher-Scientific-To-Global- Manufacturing-Consortium/default.aspx
							https://www.prnewswire.com/news-releases/ology-bioservices-inovic partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million-
	Ology Bioservices	Manufacturing (Inovio)	DNA	Unknown	Unknown	Alachua, Florida	partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million- department-of-defense-grant-301028626.html

Country	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity	Location	Sources
	TriLink (Maravai LifeSciences company)	Manufacturing self- amplifying RNA (saRNA) (imperial college london)	RNA	Unknown	Provider of cap analog component for RNA technology manufacture	San Diego, California	https://www.trliinkbiotech.com/press-releases/trliink-biotechnologies- and-imperial-college-london-announce-collaboration-to-produce- sama-for-covid-19-vaccine-development
							https://www.cytovance.com/manufacturing
	Cytovance Biologics	Manufacturer (Akshaya Bio)			up to 2,000L bioreactors	Oklahoma City	https://www.contractpharma.com/contents/view_breaking-news/2020- 04-24/cytovance-and-akshaya-enter-vaccine-collaboration/
	AveXis (subsidiary of Novartis)	Manufacturing (AAVCOVID vaccine program Massachusetts Eye and Ear and Massachusetts General Hospital)		Unknown	Unknown	Bannockburn, Illinois	https://masseyeandear.org/news/press-releases/2020/05/aavcovid- vaccine-program-enters-manufacturing-agreement-with-avexis
	Kindred Biosciences. Inc	Manufacture (Vaxart)	VVnr				https://kindredbio.com/frontpage/kindred-biosciences-announces- expansion-of-manufacturing-agreement-with-vaxart-for-covid-19-and- other-vaccine-candidates/
	Merck & Co.	Manufacturer (J&J)	VVnr	Unknown	US government is providing 269million to support Merck to adapt and make available facilities for J&J production	Rockingham; West Point	https://www.nytimes.com/2021/03/02/us/politics/merck-johnson- johnson-vaccine.html
	Ocugen	Manufacture (Covaxin)	IV				https://www.globenewswire.com/news- release/2021/02/02/2168331/0/en/Ocugen-and-Bharat-Biotech- Announce-Execution-of-Definitive-Agreement-for-the- Commercialization-of-COVAXIN-in-the-US-Market.html
							https://ir.altimmune.com/news-releases/news-release- details/altimmune-adds-lonza-manufacturing-partner-supply- adcovidtm-its
	Lonza	Manufacture (Altimmune)	VVnr			Houston	https://www.reuters.com/article/us-health-coronavirus-lonza- altimmune-idUSKBN2B40K8
	Vigene Biosciences	Manufacture (Altimmune)	VVnr				https://ir.altimmune.com/news-releases/news-release- details/altimmune-announces-manufacturing-agreement-vigene- biosciences
	Ajinomoto Bio-Pharma	Fill and Finish (AstraZeneca)	VVnr			San Diego	https://ajibio-pharma.com/news-post/ajinomoto-bio-pharma-services- expands-manufacturing-agreement-with-astrazeneca-to-include-drug- product-manufacturing/
	Avid Bioservices	Manufacturer (TerraCoV2)			11,000 litres.	Tustin, California	https://www.oragenics.com/news-media/press- releases/detail/110/oragenics-signs-process-development-and- manufacturing
	Baxter Biopharma	Fill and Finish (Moderna)	RNA	60-90 million doses per year		Indiana	https://www.baxter.com/baxter-newsroom/baxter-biopharma- solutions-and-moderna-announce-agreement-fillfinish-manufacturing
Usbekistan							https://www.prpourguire.co.uk/nours.releases/rtif.co.uk/nours.releases
	LAXISAM	Manufacture (Sputnik V)	VVnr	10 million doses in 2020			https://www.pmewswire.co.uk/news-releases/rdif-and-laxisam-agree-to-supply-up-to-35-million-doses-of-sputnik-v-vaccine-to-uzbekistan-853729566.html
Viet Nam					Signed Memorandum of Understanding with Finlay Vaccine Institute		
	Vabiotech	Manufacturer	PS (potential VVr & VVnr)	Unknown	Partnership with University of Bristol (UK)		https://vietnam.vnanet.vn/english/vabiotecha-leading-vaccine- manufacturer-in-vietnam/450213.html

Q		Fattan	Variation Blass	Production Quantity	Notes on Production Capacity and	1	
Country	Company	Function	Vaccine Platform	Estimate / Time	Availability	Location	Sources https://iapreport.
	Sinergium Biotech S.A.	Manufacturing (influenza, HPV & pneumococcal)	IV, VLP, PS & LAV	17 million doses per year (influenza)		Garin	org/img/pdf/Sinergium_Biotech_Lobos_IAP_2018_ Submission_website.pdf https://www.infobae_
					2 sites: one for "production of APIs, equipped with bacterial fermentation		com/salud/ciencia/2020/12/03/la-conexion-local-de- la-vacuna-rusa-sputnik-v-que-laboratorios-podrian-
					capacities and also hosting mass cell culture areas", another for "filling,		producirla-en-la-argentina/ https://www.gemabiotech.com/?page_id=2723#at-
Argentina	Biosidus	Manufacturing (biosimilars)		Unknown	lyophilization and packaging operations"	Buenos Aires	a-glance https://www.biosidus.com/institutional.php
					Cell engineering to Active		https://www.infobae. com/salud/ciencia/2020/12/03/la-conexion-local-de-
	Gema biotech (member of Amega Biotech)	Manufacturing (biologics)		Unknown	Pharmaceutical Ingredient (API) to Finished Product (PT)	Santa Fe	la-vacuna-rusa-sputnik-v-que-laboratorios-podrian- producirla-en-la-argentina/
							https://www.infobae. com/salud/ciencia/2020/12/03/la-conexion-local-de-
	HLB Pharma	Manufacturing (biosimilars)		Unknown		Buenos Aires	la-vacuna-rusa-sputnik-v-que-laboratorios-podrian- producirla-en-la-argentina/
					Partnership with CEPI		https://www.cslbehring.com/vita/2020/csl-starts-
					Development of University of Queensland Vaccine has been		manufacturing-a-potential-covid19-vaccine
	CSL / Segirus	Manufacturing (University of Queensland vaccine)	PS and IV	51 million doses beginning mid 2021	suspended so potential for another PS candidate to be manufactured here.	Melbourne	https://www.livemint.com/news/world/brazil- approves-emergency-use-of-astrazeneca-sinovac- vaccines-against-covid19-11610928409770.html
Australia	SOLY SOURCE	queen island vaccine)	T O UNIO 11	1110 2021	Has infrastructure for large-scale vaccine production	Molodino	Taken to against correct projects for residual
					Has experience with all mammalian		
			Various platforms		cell lines		https://www.lsq.com.au/queensland-companies-to- lead-the-way-in-on-shore-covid-19-vaccine-
	Thermo Fisher (Patheon)	Manufacturing Biologics	(specifics unknown)	270 million doses of bacterial	250-2000L fed batch	Brisbane	manufacture/
				antigens per year			
Bangladesh				20 million doses of various viral antigens per year	Confirmed additional capacity		
	Incepta Pharmaceuticals	Manufacturin	Various platforms	500 million vials per year fill &	They can start with Fill and Finish but	Dhala	Lucius de la constant
	Ltd	Manufacturing	(specifics unknown)	finish	would want to do more in the future. Suspension and continuous	Dhaka	http://inceptavaccine.com/antigen-bulk.php
					mammalian cell culture production		
					Suspension cell culture contains 2 x 10,000L bioreactors		
Belgium	Sanofi	Manufacturing (biologics / MABs)		Unknown	Perfusion cell culture contains 3 x 4,000L bioreactors	Geel	https://www.pharmaceutical-technology.com/projects/sanofi-biologics-plant-expansion-geel/
							https://www.sanofi.com/-/media/Project/One- Sanofi-Web/Websites/Global/Sanofi-
Brazil	Sanofi (Medley)	Manufacturing	Various platforms (specifics unknown)	Unknown		Campinas, Sao Paulo	COM/Home/common/docs/download-center/CSR- Report-Sanofi-Brazil-2017.pdf?la=en
	Libbs Farmaceutica	Manufacturing (biologics)	(Unknown		Sao Paulo	https://butantan.gov.br/instituto-butantan/main- products
	Libbs Farmacedica	ivaridiacturing (biologics)		Oliklowii	Confirmed additional capacity:	Gao i adio	products
					Biolyse can repurpose their facility in		
1		1	1		a few months to help manufacture		
	Biolyse Pharma	Manufacturer (mAb/sterile injectibles)	VVns	400,000 per week	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license	St. Catharines, Ontario	
Canada	Biolyse Pharma		VVns	400,000 per week	a few months to help manufacture COVID-19 vaccines if given the	St. Catharines, Ontario	
Canada		injectibles)		400,000 per week	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year		https://www.theglobeandmail.com/canada/article- president-of-montreal-company-pnuvax-says-
Canada	PnuVax	injectibles) Manufacturer biologics Aseptic fillling, packaging	VVns LAV and PS	400,000 per week	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft*2 75,000L production	Montreal, Quebec	president-of-montreal-company-pnuvax-says- ottawa-passed-on-its-offer/
Canada		injectibles) Manufacturer biologics		400,000 per week	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year		president-of-montreal-company-pnuvax-says-
Canada	PnuVax	injectibles) Manufacturer biologics Aseptic fillling, packaging		400,000 per week	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year	Montreal, Quebec Winnipeg, Manitoba	president-of-montreal-company-pnuvax-says- ottawa-passed-on-its-offer/
Canada	PnuVax Emergent BioSolutions Changchun BCHT	Injectibles) Manufacturer biologics Aseptic fillling, packaging and warehousing	LAV and PS		a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year	Montreal, Quebec Winnipeg, Manitoba Jilin	president_of-montreal_company_pnuvax-says_ ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-lid.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine-
Canada	PnuVax Emergent BioSolutions Changchun BCHT	Injectibles) Manufacturer biologics Aseptic fillling, packaging and warehousing	LAV and PS		a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year	Montreal, Quebec Winnipeg, Manitoba Jilin	president-of-montreal-company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.ccbcht.nel/changchun-bcht- biotechnology-co-ild-html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory
Canada	PnuVax Emergent BioSolutions Changchun BCHT	Injectibles) Manufacturer biologics Aseptic fillling, packaging and warehousing	LAV and PS LAV and IV IV & PS (egg based,	Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft²2 75,000L production Could do 20 - 100 million a year depending on the yield	Montreal, Quebec Winnipeg, Manitoba Jilin	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.cebcht.net/changchun-bcht- biotechnology-co-itd.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factor/ https://www.manufacturingchemist.
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co.	Injectibles) Manufacturer biologics Aseptic fillling, packaging and warehousing	LAV and PS		a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year	Montreal, Quebec Winnipeg, Manitoba Jilin	president-of-montreal-company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-id-html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist.
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co.,	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza)	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft/2 75,000 production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.cabcht.net/changchun-bcht- biotechnology-co-litd.html https://www.cabcht.net/changchun-bcht- biotechnology-co-litd.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343)
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd.	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza)	LAV and IV LAV and IV IV & PS (egg based, cell based and	Unknown 25 - 50 million doses per year (influenza) Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ² 2 75,000 production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase It trials two 2,000 production lines and can	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain &	president_of_montreal_company_pnuvax-says_ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht-biotechnology-co-id-html https://www.scmp.com/article/617256/sanofi-aventis-invest-700m-yuan-shenzhen-flu-vaccine-factory https://www.manufacturingchemist. com/news/article_page/Sanofi-Aventis vaccine_plant in China sets new record (40343 http://en.zhifeishengwu.com/about/zfgk/ http://en.zhifeishengwu.com/about/zfgk/
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co.,	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza)	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ²² 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-itd.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factony https://www.manufacturingchemist. com/news/article_pagerSanofi- Aventis vaccine_plant_in_China_sets_new_record (40343) http://www.unitedbiopharma.com/news_detail.php? id=368 http://www.unitedbiopharma.com/news_detail.php? id=368 http://www.unitedbiopharma.com/news_detail.php? id=368 http://www.unitedbiopharma.com/news_detail.php? id=368
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd.	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft/2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain &	president-of-montreal-company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.cebcht.net/changchun-bcht- biotechnology-co-itd-html https://www.cebcht.net/changchun-bcht- biotechnology-co-itd-html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis-vaccine_plant_in_China_sets_new_record /40343 http://en.zhifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/news_detail.php2 id=369 https://ispe.org/pharmaceutical- engineering/speak/met-pfizer-inc-2019-category- winner-facility-integration
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft/2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines Two 2,000L bioreactors (with room for more)	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ² 2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines Two 2,000L bioreactors (with room for more) A50,000m2 facility Specializes in mammalian cell	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain &	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.cbc.bt.net/changchun-bcht- biotechnology-co-itd.html https://www.scb.bt.net/changchun-bcht- biotechnology-co-itd.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_china_sets_new_record (40343 http://en.zhifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/news_detail.php? id=369 https://spe.org/pharmaceutical- engineering/ispeak/meet-of/zer-inc-2019-category- winner-facility-integration https://www.fiercepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield depending on the yield view of the production could do 20 - 100 million a year depending on the yield view of the production of the pro	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft ² 2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines Two 2,000L bioreactors (with room for more) A50,000m2 facility Specializes in mammalian cell	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft*2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines Two 2,000L production lines and can be upraded to twelve 2,000L lines GMP 200L/500L/500L/500L/500L/500L/500L/500L/	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft*2 75,000L production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L bioneactors (with room for more) A 50,000m2 facility Specializes in mammalian cell derived biologic products GMP 200L/500L/200L facility Confirmed additional capacity: They have capacity to manufacture millions' of vaccines. They have gone public about this capacity and season the confirmed additional capacity.	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield could be confirmed and the yield seems of the country of th	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft*2 75,000 production Could do 20 - 100 million a year depending on the yield 25 million doses of influenza vaccine per season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines 17 more) A 50,000m2 facility Specializes in mammalian cell derived biologic products GMP 200L/500L/200L facility Confirmed additional capacity: They have capacity to manufacture 'millions' of vaccines. They have gone public about this capacity and have approached the Danish government but there is no concrete	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president-of-montreal-company-pnuvax-says- ottawa-passed-on-tts-offer/ https://www.cbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-tld.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=368 https://ispe.org/pharmaceutical- engineering/ispeat/meet-of/zer-inc-2019-category- winner-facility-integration https://www.firecepharma.com/pharma-asia/pfizer-
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield could be considered to the production of the production	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cbcht.net/changchun-bcht- biotechnology-co-ild.html https://www.scmp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis-vaccine_plant_in_China_sets_new_record /40343 http://en.zhifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/news_detail.php2 id=369 https://ispe.org/pharmaceutical- engineering/speak/met-offizer-inc-2019-category- winner-facility-integration https://www.fercepharma.com/pharma-asia/pfizer- halls-biosimilar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxi https://www.thelocal.dk/20210202/danish-
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics)	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant)	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield depending on the yield vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines with the confirmed additional capacity: They are considered with the confirmed additional capacity: They have capacity of vaccines. They have gone public about this capacity and have approached the Danish government but there is no concrete proposals and want to engage in production. They would be willing to speak to C-TAP and not against exploring compulsory licensing.	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.csbcht.net/changchun-bcht- biotechnology-co-lid.html https://www.scpb.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=369 https://ispe.org/pharmaceutical- engineering/ispeak/meet-ofizer-inc-2019-category- winner-facility-integration https://www.fiercepharma.com/pharma-asia/pfizer- halts-biosimillar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxl
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXI Biologics) CMAB Biopharma	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield depending on the yield vaccine green season Their own COVID-19 vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines vaccine per season so the confirmed and the vaccine green season the production lines and can be upraded to twelve 2,000L lines which is season to the vaccine green season the confirmed and ditional capacity. They have capacity to manufacture millions' of vaccines. They have gone public about this capacity and have approached the Danish government but there is no concrete progress. They are looking for concrete proposals and want to engage in production They would be willing to speak to C-TAP and not against exploring compulsory licensing.	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China Hangzhou Suzhou	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.cbcht.net/changchun-bcht- bitoechnology-co-itd.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-itd.html https://www.scbcht.net/changchun-bcht- bitolechnology-co-itd.html https://www.scbcht.net/changchun-bcht- pitolechnology-co-itd.html https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis-vaccine_plant_in_China_sets_new_record /40343 http://en.zbifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/about/zfgk/ http://www.unitedbiopharma.com/about/zfgk/ http://www.unitedbiopharma.com/about/zfgk/ https://www.thelocal.dk/20210202/danish- gaingenfinglia-programs.china-amid-ever- crowded-market-sells-plant-to-wuxi https://www.thelocal.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine- production
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXI Biologics) CMAB Biopharma	Manufacturer biologics Aseptic fillling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield depending on the yield vaccine is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines two 2,000L production lines and can be upraded to twelve 2,000L lines with the production of the product	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing HuKou, Tawain & Yangzhou, China Hangzhou Suzhou	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-lid.html https://www.scpb.com/article/817256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://en.zhifeishengwu.com/about/zfgk/ http://en.zhifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/news_detail.php? d=369 https://www.unitedbiopharma.com/news_detail.php? d=369 https://www.treiocai.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine-
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics) CMAB Biopharma	Manufacturer biologics Aseptic filliling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (influenza) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics)	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if 25,000 hr 275,000 L production Could do 20 - 100 million a year depending on the yield separation of the production of the producti	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing Hulkou, Tawain & Yangzhou, China Hangzhou Suzhou Kvistgaard	president_of-montreal_company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.csbcht.nel/changchun-bcht- biotechnology-co-lid.html https://www.scpb.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzben-filu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://www.unitedbiopharma.com/news_detail.php? id=389 https://ispe.org/pharmaceutical- engineering/ispeak/meet-pfizer-inc-2019-category- winner-facility-integration https://www.fiercepharma.com/pharma-asia/pfizer- halts-biosimilar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxi https://www.thelocal.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine- production https://www.teuters.com/article/health-coronavirus- denmark-vaccine-idUSL112L000Q
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics) CMAB Biopharma Bavarian Nordic	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) API Manufacturing (insulin and biologics) API Manufacturer	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield separate of the production could do 20 - 100 million a year depending on the yield separate of the production of the yield separate of yield separate yield separate yield separate yield separate yield separate yield yield separate yield yield separate yield	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing Hulkou, Tawain & Yangzhou, China Hangzhou Suzhou Kvistgaard	president_of-montreal_company_pnuvax-says_ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-lid.html https://www.scpb.com/article/817256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40343 http://en.zhifeishengwu.com/about/zfgk/ http://en.zhifeishengwu.com/about/zfgk/ http://en.zhifeishengwu.com/about/zfgk/ http://spe.org/pharmaceutical- engineering/ispea/meet-ofizer-inc-2019-category- winner-facility-integration https://www.frerepharma.com/pharma-asia/pfizer- halts-biosimilar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxi https://www.thelocal.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine- production
China	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics) CMAB Biopharma Bavarian Nordic	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) API Manufacturing (insulin and biologics) API Manufacturing (Viral Vectors, microbial	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if given the technology transfer / license Confirmed capacity 150,000 ft-2 75,000L production Could do 20 - 100 million a year depending on the yield depending on the yield very season. Their own COVID-19 vaccine is currently in Phase I trials two 2,000L brown that is currently in Phase I trials two 2,000L production lines and can be upraded to twelve 2,000L lines with the confirmed additional capacity: They have good they capacity to manufacture millions' of vaccines. They have gone public about this capacity and have approached the Danish government but there is no concrete propress. They are looking for concrete proposals and want to engage in production. They would be willing to speak to C-TAP and not against exploring compulsory licensing. Facilities to make vaccines Potentially in dicussions with Danish government. Potentially in dicussions with Danish government. Agreement signed with a European	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing Hulkou, Tawain & Yangzhou, China Hangzhou Suzhou Kvistgaard	president_of-montreal_company-pnuvax-says- ottawa-passed-on-tls-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cobcht.net/changchun-bcht- biotechnology-co-lld.html https://www.scpb.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record (40543) http://www.unitedbiopharma.com/news_detail.php? id=369 https://www.unitedbiopharma.com/news_detail.php? id=369 https://www.unitedbiopharma.com/news_detail.php? id=369 https://www.tiselocal.dk/20210202/danish- record-facility-integration https://www.fiercepharma.com/pharma-asia/pfizer- halts-biosimiliar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxl https://www.thelocal.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine- production https://www.reuters.com/article/health-coronavirus- denmark-vaccine-idUSL1N2LD0QG https://www.nature.com/articles/d43747-020- 00920-9 https://biovian.com/wp-
China Denmark Egypt	PnuVax Emergent BioSolutions Changchun BCHT Biotechnology Co. Sanofi Pasteur Chongqing Zhifei Biological Products Co., Ltd. United Biopharma Pfizer (recently sold to WuXi Biologics) CMAB Biopharma Bavarian Nordic	Manufacturer biologics Aseptic filling, packaging and warehousing Manufacture (influenza) Manufacture (influenza) Manufacture (influenza) Manufacturing (biologics) Manufacturing (mAb) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) API Manufacturing (insulin and biologics) API Manufacturer Manufacturer	LAV and PS LAV and IV IV & PS (egg based, cell based and recombinant) PS and IV	Unknown 25 - 50 million doses per year (influenza) Unknown Unknown Unknown	a few months to help manufacture COVID-19 vaccines if given the technology transfer / license COVID-19 vaccines if 25 million on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 - 100 million a year depending on the yield sold of 20 million and year of 20 million	Montreal, Quebec Winnipeg, Manitoba Jilin 4 production lines Shenzhen Chongqing Hulkou, Tawain & Yangzhou, China Hangzhou Suzhou Kvistgaard	president-of-mortea-company-pnuvax-says- ottawa-passed-on-its-offer/ https://www.emergentbiosolutions.com/node/148 https://www.cbcht.net/changchun-bcht- biotechnology-co-itd.html https://www.scp.com/article/617256/sanofi- aventis-invest-700m-yuan-shenzhen-flu-vaccine- factory/ https://www.manufacturingchemist. com/news/article_page/Sanofi- Aventis vaccine_plant_in_China_sets_new_record /40343 http://en.zhifeishengwu.com/about/zfgk/ http://www.unitedbiopharma.com/news_detail.php? (d=389 https://spe.org/pharmaceutical- engineering/speak/meet-pfizer-inc-2019-category- winner-facility-integration https://www.fercepharma.com/pharma-asia/pfizer- halts-biosimilar-programs-china-amid-ever- crowded-market-sells-plant-to-wuxi https://www.thelocal.dk/20210202/danish- company-offers-to-help-with-covid-19-vaccine- production https://www.reuters.com/article/health-coronavirus- demark-vaccine-idUSL1N2LD0O/G https://www.nature.com/articles/d43747-020- 00920-9

Country	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity and Availability	Location	Sources
	Sanofi Pasteur	Manufacturing	IV & PS (egg based, cell based and recombinant)			Val-de-Reuil Marcy-L'Etoile	https://www.lefigaro.fr/societes/covid-19-quels- sont-les-sites-qui-produiront-les-vaccins-en-france- 20210203
	Sanon Fasteur	Manufacturing	IV & PS (egg based, cell based and			iwarcy-L Etolie	https://www.lefigaro.fr/societes/covid-19-quels- sont-les-sites-qui-produiront-les-vaccins-en-france-
France	Sanofi Pasteur Servier	Manufacturing (antigen) Manufacturing	recombinant)	Unknown	Up to 2,000L bioreactor capacity	Vitry-sur-Seine Gidy	20210203
	Novasep	Manufacturing (biologics)		Unknown	Purification of APIs and chromatography	Pompey	https://www.novasep.com/home/about- novasep/our-locations-worldwide.html
	Catalent Inc.	Fill and Finish		Unknown	, , ,	Limoges	
Hungary	Fluart Innovative Vaccines Kft	Manufacture (influenza)	IV or PS	Unknown		Pilisborosjeno	
Iceland	Alvotech	Biosimilar Manufacturer		Unknown	Interested if know-how for API	Reykjavik	
	Cipla USV Biologics	Biosimilars production		Unknown	production is available	Mumbai Mumbai	
		Biologics and biosimilars					https://www.kemwellbiopharma. com/sites/default/files/2019-08/Kemwell-services-
	Kemwell Biopharma Biological E Ltd.	production Manufacturing	PS (VLP?)	Unknown Unknown	Over 4,000L bioreactors capacity Bulk manufacturing facility	Bengalaru Ranga Reddy District	overview.pdf
	BioMeed Pvt. Ltd	Manufacturing	PS & IV	Unknown	J	Ghaziabad	
	Cadila Healthcare Limited	Manufacturing	PS, IV & VLP	Unknown		Ahmedabad	
	Chiron Behering Dano Vaccine &	Manufacturing (rabies)	IV	Unknown		Ankleshwar, Bharuch	
	Biological Pvt. Ltd	Manufacturing Manufacturing (BCG	PS	Unknown		Hyderbad Gummidipoondi	
India	Green Signal BioPharma Ranbaxy Lab	vaccine) Manufacturing	LAV PS	Unknown Unknown		Chennai Bangalore	
	Shantha Biotechnics Ltd.	Manufacturing	LAV, VLP, PS	Unknown		Two locations	
	GlaxoSmithKline (GSK) Sanofi Pasteur	Manufacturing Manufacturing	PS PS, IV, LAV	Unknown Unknown		Ambad-Pathardi, Nashik	
					API manufacturing facility		
	Reliance Life Science	Manufacturing	PS	Unknown	They also have their own COVID vaccine in the pipeline	Navi Mumbai	
	Diagram (Oursell)	Manufacturia		Haba ana	Syngene is in collaboration to	Barratan and Observat	https://www.biocon.com/biocon-presented-insights- into-clinical-study-that-enabled-dcgi-approval-of-
	Biocon (Syngene)	Manufacturing		Unknown	provide reagents for vaccines	Bangalore and Chennai	itolizumab-for-covid-19/ https://www.fiercepharma.
	Pfizer	Fill and Flnish		Unknown		Visakhapatnam	com/manufacturing/pfizer-sterile-plant-india- slapped-warning-letter
	Haffkine Biopharmaceutical Corporation	Manufacturing		Unknown			
	Corporation	inanalacting					http://www.bayerpaul.com/en-Posts- 204/VACCINES#:~:text=Human%20vaccine%
Iran	Bayerpaul Group	Manufacture (influenza)	IV (& LAV?)	20 million doses		Tehran	20production%20line%20with,requirements% 20and%20also%20WHO%20standards.
					One facility in operation and another facility in Carlow under construction		https://msd-ireland.com/about-us/msd-ireland-our-
	Merck Sharp & Dohme	Formulate and Fill		Unknown	and operational in 2023	Carlow	sites https://msd-ireland.com/about-us/msd-ireland-our-
	Merck Sharp & Dohme	Manufacturing	VVnr - likely more	Unknown		Brinny, Co.Cork	sites https://msd-ireland.com/about-us/msd-ireland-our-
	Merck Sharp & Dohme	Manufacturing	VVnr - likely more	Unknown		Swords	sites https://msd-ireland.com/about-us/msd-ireland-our-
	Merck Sharp & Dohme	Manufacturing	VVnr - likely more	Unknown	Six times 15,000L lines Four times 15,000L lines	Cruiserath	sites
Ireland					Unclear if they will manufacture J&J		
	Janssen	Manufacturing		Unknown	vaccine at this location	Ringaskiddy, Co.Cork	https://www.wuxibiologics.com/News_Media-
					6,000L bioreactor capacity and 48,000L fed-batch. WuXi Vaccines		Press Release-2020- 03 11 WuXi Biologics Completes Weather Tight Seal of its Biologics Manufacturing Facility in I
					dedicated to vaccine manufacturing, expected to begin in 2024. Unclear if		reland.html
	WuXi Biologics	Manufacturing (biologics)	Not specified	Unknown	Covid-19 vaccine will be manufactured.	Dundalk	https://www.idaireland.com/newsroom/wuxi- biologics-making-dundalk-a-world-leader-in-bi
	Pfizer	Manufacturing, Fill and Finish	PS	Unknown	Aiding with quality testing for the Pfizer facility in Beligum	Grange Castle	https://www.pfizer.ie/operations
					If facility approved, able to support		https://en.globes.co.il/en/article-mapi-pharma-in- talks-to-produce-covid-19-vaccine-in-israel-
Israel	Mapi Pharma Ltd.	Manufacturing and storage	Not specified	Unknown	supply of COVID vaccines	Jerusalem	1001344946 https://www.reuters.com/article/us-teva-pharm-ind-
	T	Manufacturing			In dicussion with originators of original vaccines to co-produce		covid-exclusive/exclusive-teva-pharm-in-talks-to- co-produce-covid-19-vaccines-ceo-says-
	Teva	Ů			Possibly manufacturing the		idUSKBN2AA20D https://www.toscanalifesciences.
	BiOMVis	Manufacturing (Outer Membrane Vescicles OMVs)	PS	Unknown	University of Trento COVID vaccine candidate	Siena	org/it/2020/04/covid-19-piattaforma-di-biomvis-si- dimostra-efficace-nella-ricerca-di-un-possibile- vaccino-2/
Italy	Biomedica Foscama	Manufacturing (Sputnik V)	VVnr	Unknwon	No contract has been signed yet.	Ferentino	https://www.alessioporcu.it/articoli/vaccino-sputnik- pronte-biomedica-acs-dobfar/
,	Acs Dobfar	Manufacturing (Sputnik V)	VVnr	Unknown	No contract has been signed yet.	Anagni	https://www.alessioporcu.it/articoli/vaccino-sputnik- pronte-biomedica-acs-dobfar/
		Manufacturing (Cell therapy			1 x stream for 200L lentiviral and retroviral vector manufacturing in		
	ACG Biologics	and viral vectors) Manufacture (LNP-	RNA & IV (cell based	Unknown	fixed-bed bioreactor Developing large scale production	Milan, Bresso Kitamoto City, Saitama	https://www.daiichisankyo.
	Daiichi Sankyo	encapsulated mRNA)	and egg based)	Unknown	system	Prefecture	com/media/press_release/detail/index_3124.html https://www.sciencedirect.
	BIKEN Co., Ltd	Manufacturing (influenza)	IV or PS	Unknown		Kanonji	com/science/article/pii/S0264410X20315851? dgcid=rss_sd_all#s0080
						Chuo-ku, Tokyo & Gosen City, Niigata	https://www.sciencedirect. com/science/article/pii/S0264410X20315851?
Japan	Denka Seiken Co., Ltd	Manufacturing (influenza)	IV or PS IV or PS (egg and cell	Unknown	Produce vaccines for 57 million	Prefecture	dgcid=rss_sd_all#s0080 https://www.kmbiologics.
•	KM Biologics Co., Ltd.	Manufacturing (influenza)	lV or PS (egg based,	Unknown	people in an influenza pandemic	Koshi-shi, Kumamoto	com/en/about_us/locations.html https://www.sciencedirect.
l				I .	1	1	com/science/article/pii/S0264410X20315851?
	Sanofi Pasteur	Manufacturing (influenza)	cell based and recombinant)	Unknown			dgcid=rss_sd_all#s0080
	Roche (Chugai	Manufacture (no covid	recombinant)		36,000L of antibody production	Liteumomius au d.192	dgcid=rss_sd_all#s0080 https://www.biopharma-reporter. com/Article/2015/10/28/Roche-s-Chugai-investing-
			cell based and recombinant) RNA (possibly)	Unknown	36,000L of antibody production capacity (large capacity)	Utsunomiya and Ukima	dgcid=rss_sd_all#s0080 https://www.biopharma-reporter.

				Production Quantity	Notes on Production Capacity and		
Country	Company	Function	Vaccine Platform	Estimate / Time	Availability	Location	Sources
Mexico							https://www.researchgate. net/publication/51229908 Domestic influenza vac
							cine production in Mexico A state- owned and a multinational company working to
			IV and PS (egg based,				gether for public health#:~:text=Under%20this% 20agreement%2C%20sanofi%20pasteur.
	Sanofi Pasteur	Manufacturing antigen (influenza)	cell based and recombinant)	30 million doses per year (influenza)			inactivated%20split%2Dvirion%20influenza% 20vaccine.
Nicaragua	Mechnikov Institute	Manufacture (influenza)		Unknown	Mammalian cells capacity 3 x 500L,		
Poland					4 x 2,000L		https://polabormobiologica.com/ap/about.us/aus
	Polpharma Biologics	Manufacture (biologics)		Unknown	Expansion available to 30,000L	Warsaw	https://polpharmabiologics.com/en/about-us/our- sites#warsaw
					Confirmed additional capacity:		
					Looking to scale up and upgrade facilities		
Pakistan					Possibility for 20million vials a year of fill and finish (in six months)		
					Possibility for end-to-end vaccine manufacturing (18 months incl. tech		
					transfer)		
	Getz Pharma	Manufacturer	Various platforms		Happy to engage with C-TAP 1,000L mammalian cell		http://www.eubiologics.
	Eubiologics	Manufacturer		Unknown	600l microbial fermentation	Gangwon-do	com/en/gmp_plant/plant_overview.php
	Harri Dhaman diad						https://www.reuters.com/business/healthcare- pharmaceuticals/exclusive-skorea-talks-with-mma-
Republic of Korea	Hanmi Pharmaceutical co., ltd.	Manufacturer	RNA			Seoul	vaccine-makers-make-up-1-bln-doses-govt-2021- 07-05/
							https://www.reuters.com/business/healthcare- pharmaceuticals/exclusive-skorea-talks-with-mrna-
	Quratis Co Ltd.	Manufacturer	RNA			Seoul	vaccine-makers-make-up-1-bln-doses-govt-2021- 07-05/
	Microgen	Manufacturing (no known COVID plans)	IV and LAV	Unknown		Moscow. State owned facility	
Russia	SPbNIIVS	Manufacturer		Unknown		St Petersburg	https://www.sciencedirect. com/science/article/pii/S0264410X20307957
	FORT National						https://tadviser.com/index.php/Company:
	Biopharma	Manufacture		Unknown		Ryazan	Fort_Biopharmaceutical_company http://www.arabio.com/Facility-07.html#:~;
Saudi Arabia	Arabio	Manufacturer (influenza, amongst others)	IV, PS (possibly LAV & VLP)	Unknown	Two separate process lines (Vial and Syringe)	Makkah	text=The%20capacity%20of%20the%20system. production%20capacity%201%2C270%20lit%2Fh.
					Potential manufacture agreement (letter of intent to collaborate) with		
Senegal		Manufacture (yellow fever			Univercells to supply COVID-19 vaccine shots to countries across		https://www.reuters.com/world/africa/exclusive- boost-africa-senegal-aims-make-covid-shots-next-
	Institut Pasteur	vaccine)	IV (egg based)		West Africa	Dakar	<u>year-2021-06-06/</u>
	GlaxoSmithKline (GSK)	Manufacturer		Llakaana	Possibly fulfilling Fill and Finish capabilities for a COVID vaccine	Tues	https://www.businesstimes.com.sg/government- economy/pharmaceutical-firms-to-manufacture-
	Giaxosilitiikiile (GSK)	Fill and Finish		Unknown	Potential that Moderna candidate to	Tuas	https://www.straitstimes.
					be manufactured at this facility in the future		com/singapore/health/singapore-boosting-capacity- for-fast-production
					Bioreactior at 2,000L and 20,000L	_	https://pharma.lonza.com/about/locations/tuas-
Singapore	Lonza AG	Manufacturer	RNA	Unknown	batches	Tuas	<u>singapore</u>
Į.						Woodlands Industrial	
	Takeda	Manufacturer (biologics)				Woodlands Industrial Park, Singapore	https://www.amgen.com.sg/about/amgen-
	Takeda	Manufacturer (biologics)				Woodlands Industrial Park, Singapore	https://www.amgen.com.sg/about/amgen- singapore/amgen-singapore-manufacturing- capabilities/
	Takeda	Manufacturer (biologics)			Fixed bioreator vessels with 20,000L	Woodlands Industrial Park, Singapore	singapore/amgen-singapore-manufacturing- capabilities/
Sweden	Amgen	Manufacturer		Linknown	of cells and growth media	Park, Singapore Tuas	singapore/amgen-singapore-manufacturing-
Sweden Switzerland				Unknown Unknown		Park, Singapore	singapore/amgen-singapore-manufacturing- capabilities/ https://www.amgenscience.com/features/the-next-
Switzerland	Amgen AstraZeneca	Manufacturer Manufacturing			of cells and growth media	Park, Singapore Tuas Södertälje	singapore/amgen-singapore-manufacturing- capabilities/ https://www.amgenscience.com/features/the-next- generation-of-biotech-manufacturing/
	Amgen AstraZeneca Lonza Group AG	Manufacturer Manufacturing Fill and Finish	DNA	Unknown	of cells and growth media	Park, Singapore Tuas Södertälje Stein	singapore/amgen-singapore-manufacturing- capabilities/ https://www.amgenscience.com/features/the-next- generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid- 19-vaccine/
Switzerland	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions	Manufacturer Manufacturing Fill and Finish Manufacturing	DNA	Unknown	of cells and growth media	Park, Singapore Tuas Södertälje Stein Bern	singapore/amgen-singapore-manufacturing- capabilities/ https://www.amgenscience.com/features/the-next- generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-
Switzerland	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish	DNA	Unknown	of cells and growth media	Park, Singapore Tuas Södertälje Stein Bern	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#:text=Mycenax*s%
Switzerland Thailand	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines	DNA and potentially	Unknown Unknown	of cells and growth media Large capacity	Park, Singapore Tuas Södertälje Stein Bern	singapore/amgen-singapore-manufacturing-capabilities/ https://hww.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#:text=Mycenax's% 20protein%2Ddrug%2Dmanufacturing%20process, in%20the%20development%200f%
Switzerland Thailand Taiwan	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing		Unknown	of cells and growth media	Park, Singapore Tuas Södertälje Stein Bern	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-blotech-manufacturing/ https://blonet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#:~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20the% 20biopharmaceuticals.
Switzerland Thailand	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines	DNA and potentially	Unknown Unknown	of cells and growth media Large capacity	Park, Singapore Tuas Södertälje Stein Bern	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ https://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#:~text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20of% 20biopharmaceuticals.
Switzerland Thailand Taiwan	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics)	DNA and potentially	Unknown Unknown	of cells and growth media Large capacity	Tuas Södertäije Stein Bern Bangkok	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#:~text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20of% http://www.pasteu.tri/index.php? potion=com.content&view=article&id=161&temid=
Switzerland Thailand Taiwan	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics)	DNA and potentially	Unknown Unknown	of cells and growth media Large capacity	Tuas Södertäije Stein Bern Bangkok	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#~-text=Mycenax's% 20porotein%20brug%20manufacturing%20process, in%20the%20development%20of%20development%20brug%20bolparmaceuticals. http://www.pasteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-
Switzerland Thailand Taiwan	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B.	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus-polio and bacillus Calmetter)	DNA and potentially	Unknown Unknown Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors	Tuas Södertälje Stein Bern Bangkok Tunis	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-blotech-manufacturing/ https://blonet-asia.com/update-on-thallands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%20drug%20manufacturing%20process, in%20the%20development%20et% 20blopharmaceuticals. http://www.pasteur.tn/index.php? gslon=com_content&view=article&id=161&Itemid=192
Switzerland Thailand Taiwan	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute)	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus-polio and bacillus Calmetter)	DNA and potentially	Unknown Unknown Unknown	of cells and growth media Large capacity	Tuas Södertälje Stein Bern Bangkok Tunis	singapore/amgen-singapore-manufacturing-capabilities/ https://hwww.amgenscience.com/features/the-next-generation-of-blotech-manufacturing/ https://blonet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-ylew&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20dr% 20biopharmaceuticals. http://www.asteur.tn/index.php? option=com_content&view=article&id=161&Itemid= 199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V. (subsidiary recently	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus-polio and bacillus Calmette-Guerin vaccines)	DNA and potentially	Unknown Unknown Unknown 20 million doses a year	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity	Tuas Södertäije Stein Bern Bangkok Tunis	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-blotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20th% 20biopharmaceuticals. http://www.assteur.tn/index.php? option=com_content&view=article&id=161&itemid= 199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V. (subsidiary recently	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics)	DNA and potentially	Unknown Unknown Unknown 20 million doses a year	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april:	Tuas Södertäije Stein Bern Bangkok Tunis	singapore/amgen-singapore-manufacturing-capabilities/ https://hww.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-ylew&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20dr% 20biopharmaceuticals. http://www.asteur.tn/index.php? option=com_content&view=article&id=161&Itemid= 199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V. (subsidiary recently renamed AstraZeneca)	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics)	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to	Park, Singapore Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen	singapore/amgen-singapore-manufacturing-capabilities/ https://bww.amgenscience.com/features/the-next-generation-of-blotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-ylew&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20dr% 20biopharmaceuticals. http://www.asteur.tn/index.php? option=com_content&view=article&id=161&Itemid= 199 https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bithoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V, (subsidiary recently v, (subsidiary recently v, renamed AstraZeneca)	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus-polio and bacillus Calmette-Guérin vaccines) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (AdaptVac) Fill and Finish Manufacturing (influenza)	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#~-text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20t% 20biopharmaceuticals. http://www.assetur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dufch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://www.segirus.com/manufacturing/global-
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V. (subsidiary recently renamed AstraZeneca)	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus-polio and bacillus Calmette-Guérin vaccines) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics)	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to	Park, Singapore Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/. https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#text=Mycenax's% 20prolein%20drug%20drug%20process, in%20the%20development%20of% 20biopharmaceuticals. http://www.pasteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://www.segirus.com/manufacturing/global-manufacturing-network
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bithoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V, (subsidiary recently v, (subsidiary recently v, renamed AstraZeneca)	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing (influenza) Fill and Finish	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#~-text=Mycenax's% 20porolein%20drug%20manufacturing%20process, in%20the%20drug%20manufacturing%20process, in%20the%20drewipement%20of% 20biopharmaceuticals. http://www.pasteur.tm/index.php? phttps://inwww.pasteur.tm/index.php? https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://biwww.seqirus.com/manufacturing/global-manufacturing-network https://biwww.seqirus.com/manufacturing/global-manufacturing-network https://binam.lonza.com/bout/locations/slough-uk#~-text=Biopharmaceutical%20development%.
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V, (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing influenza) Fill and Finish Manufacturing monoclonal antibodies and recombinant proteins for mammalian	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#text=Mycenax's% 20porolen%20drug%20manufacturing%20process, in%20the%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug%20ment%20drug/s0drug/manufacturing/s0drug/manufacturing/s0drug/manufacturing-network https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/the-wa
Switzerland Thailand Taiwan Tunisia	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bithoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V, (subsidiary recently v, (subsidiary recently v, renamed AstraZeneca)	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (lactivated polic), diphtheria-telanus-polic, diphtheria-telanu	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act=view&id=18 http://www.mycenax.com.tw/#text=Mycenax's% 20porotein%20drug%20manufacturing%20process, in%20the%20drug%20drewipment%20th%20drug%20development%20fw2% 20biopharmaceuticals. http://www.pasteur.tn/index.php? aption=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://www.sedirus.com/manufacturing/global-manufacturing-network https://phama.lonza.com/about/locations/slough-uk#text=Biopharmaceutical%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmufacturingsext=Slough%20development% 20and%20anmaceuticals.
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V, (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing influenza) Fill and Finish Manufacturing monoclonal antibodies and recombinant proteins for mammalian	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-yiew&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20d% 20biopharmaceuticals. http://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://pharma loraz.com/abut/locations/slough- utk#:—text=Biopharmaceutical%20development% 20and%20manufacturing&text=Slough%20is% 20abc%20abc%20c00%20lz_development% 20abc%20abc%20c00%20lz_development% 20abc/sumanufacturing&text=Slough%20is% 20abc%20c00%20lz_development% 20abc%20colors@20lz_development% 20abc/sumanufacturing&text=Sloughmallan% 20Biopharmaceuticals.
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V, (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (biologics) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing influenza) Fill and Finish Manufacturing monoclonal antibodies and recombinant proteins for mammalian	DNA and potentially others	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#~:text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20drew/20menufacturing%20process, in%20the%20development%20dr% 20biopharmaceuticals. http://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.shp https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://pharma.lorus.com/abut/locations/slough- utk#:—text=Biopharmaceutical%20development% 20and%20manufacturing&text=Slough%20is% 20a%20128/20100%2012_development% 20and%20manufacturing&text=Slough%20is% 20a%20128/20100%2012_development% 20and%20manufacturing&tsext=Slough%20is% 20a%20128/20100%2012_development% 20alogharmaceutical%20development% 20alogharmaceutical%20development% 20alogharmaceutical%20development% 20alogharmaceutical%20development%
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bithoven Biologicals (acquired by the Serum Institute) Medimmune Pharma B. V, (subsidiary recently v, (subsidiary recently v, renamed AstraZeneca) BioConnection BV Seqirus Lonza AG AstraZeneca	Manufacturer Manufacturing Fill and Finish Manufacturing Manufacturing Fill and Finish Manufacturing Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturer (Inactivated polio, diphtheria-tetanus- polio, and bacillus Calmette- Guérin vaccines) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (influenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monoclonal antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Manufacturing (influenza)	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production	Park, Singapore Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#~-text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20d% 20biopharmaceuticals. http://www.assetur.tn/index.php? option=com_content&view=article&id=161&Itemid= 199 https://bioconnection.eu/news/adaptvac-partners-with-bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacturing/global-manufacturing-network https://www.segirus.com/manufacturing/global-manufacturing-network https://www.segirus.com/abuuflocations/slough-index-text-Biopharmaceuticals/s20development% 20de/s20de/
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V. (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus Lonza AG	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (filluenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monocional antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Fill and Finish (partially for	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this sitle Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production	Park, Singapore Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#:~:text=Mycenax's% 20porolein%2Ddrug%20manufacturing%20process, in%20the%20development%20d% 20biopharmaceuticals. http://www.assteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-health-field/ https://innovationorigins.com/dutch-field/ https://innovationorigins.com/dutch-field/ 208iophamaceuticals. https://innovationorigins.com/dutch-field/ https://innovationorigins.co
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V. (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus Lonza AG AstraZeneca CP Pharmaceuticals	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (filluenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monocional antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Fill and Finish (partially for	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vals per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&ide-18 http://www.mycenax.com.tw/#-~text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20t% 20biopharmaceuticals. http://www.assteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://www.segirus.com/manufacturing/global-manufacturing-network https://cand%20damanufacturing/set-slough-uskfrtext-Biopharmaceutical%20development%20dand%20manufacturing/set-slough-was-set-slo
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V. (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus Lonza AG AstraZeneca CP Pharmaceuticals	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (filluenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monocional antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Fill and Finish (partially for	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vals per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&ide-18 http://www.mycenax.com.tw/#-~text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20t% 20biopharmaceuticals. http://www.assteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacturie-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://www.segirus.com/manufacturing/global-manufacturing-network https://cand%20mamanufacturing/s2016%20development%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%20167%20Mammalian%2016altity%201676arearea.com/united-kingdom https://hubscontent10.betchubs/f7114882/fmergent_CDMO_Brochure_20 20.pdf https://patogent.and.com/and/acturing/a22 20.pdf https://patogent.com/and/acturing/a22 20.pdf https://patogent.com/and
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V. (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus Lonza AG AstraZeneca CP Pharmaceuticals	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (filluenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monocional antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Fill and Finish (partially for	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vials per year - and looking to help with COVID vaccine production Five 1,000L biorectors One line dedicated to AstraZeneca	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#-~text=Mycenax's% 20protein%2Ddrug%20manufacturing%20process, in%20the%20development%20t% 20biopharmaceuticals. http://www.assteur.tn/index.php? option=com_content&view=article&id=161&itemid=199 https://www.cyruspoonawallagroup.com/our-companies/bilthoven-biologicals.php https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacturie-their-covid-19-vaccine/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://innovationorigins.com/dutch-province-of-brabant-is-leading-the-way-in-the-med-tech-and-e-bealth-field/ https://www.segirus.com/manufacturing/global-manufacturing-network https://cand%20mamufacturing/set-slough-ukfrtext-Biopharmaceutical%20development%20dadf%20development%20dadf%20development%20dadf%20development%20dadf%20development%30developmentmaceuticals. https://careers.astrazeneca.com/united-kingdom https://hwww.thercepharma.com/manufacturing/az-taps-indian-pharma-wockhardt-for-uk-shot-finishing https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con/d-19-vaccine-https://hubscoture.com/ental-con
Switzerland Thailand Taiwan Tunisia The Netherlands	Amgen AstraZeneca Lonza Group AG Emergent Biosolutions Bionet-Asia Mycenax Institute Pasteur Tunis Bilthoven Biologicals (acquired by the Serum Institute) MedImmune Pharma B. V. (subsidiary recently renamed AstraZeneca) BioConnection BV Seqirus Lonza AG AstraZeneca CP Pharmaceuticals	Manufacturer Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing Fill and Finish Manufacturing of plasmid DNA for DNA vaccines Biologics Manufacturing Manufacturing (vaccines, biologics) Manufacturing (biologics) Manufacturing (biologics) Manufacturing (filluenza) Fill and Finish Manufacturing (influenza) Fill and Finish Manufacturing monocional antibodies and recombinant proteins for mammalian drugs Manufacturing (influenza) Fill and Finish (partially for	DNA and potentially others PS IV (egg and cell based)	Unknown Unknown 20 million doses a year Unknown 200-500 million doses Unknown Unknown	of cells and growth media Large capacity Six single use 2,000L bioreactors Unclear whether AZ COVID vaccine will be manufactured at this site Confirmed fill and finish capacity available from april: Fill and finish capacity of 40 to 50 million vals per year - and looking to help with COVID vaccine production	Tuas Södertälje Stein Bern Bangkok Tunis Bilthoven Nijmegen Oss Liverpool	singapore/amgen-singapore-manufacturing-capabilities/ https://www.amgenscience.com/features/the-next-generation-of-biotech-manufacturing/ https://bionet-asia.com/update-on-thailands-covid-19-vaccine/ http://www.mycenax.com.tw/en/oem.php? act-view&id=18 http://www.mycenax.com.tw/#text=Mycenax's% 20protein%2Ddrug%2Dmanufacturing%20process, in%20the%20drew@20manufacturing%20process, in%20the%20drew@20manufacturing%20process, in%20the%20drew@20menif&20dr% 20biopharmaceuticals. http://www.apsetur.tn/index.php? action=com_content&view=article&id=161<emid=199 https://bioconnection.eu/news/adaptvac-partners-with-bioconnection-to-manufacture-their-covid-19-yaccine/ https://bioconnection-to-manufacture-their-covid-19-yaccine/ https://bioconnection-to-manufacture-their-covid-19-yaccine/ https://www.seqirus.com/manufacturing/global-nanufacturing-network https://www.seqirus.com/manufacturing/global-manufacturing-network https://www.seqirus.com/manufacturing/global-manufacturing-network https://www.thebusinessdesk.com/manufacturing/development%20am%20development%20am%20development%20am%20development%20am%20development%20facturing/acturi

				Production Quantity	Notes on Production Capacity and		
Country	Company	Function	Vaccine Platform	Estimate / Time	Availability	Location	Sources
	PCI Pharma Services						
							https://www.prnewswire.com/news-releases/lonza-
							opens-worlds-largest-dedicated-cell-and-gene-
							therapy-manufacturing-facility-in-pearland-greater- houston-tx-usa-300627193.html
					300,000 square feet		https://pharma.lonza.com/about/locations/hayward-
	Lonza Group AG	Manufacture (viral vectors)		Unknown	2 x1,000L, 2x 2,000L bioreactors	Hayward	<u>california-usa</u>
							https://www.biopharma-reporter. com/Article/2016/01/08/Takeda-buys-Baxalta-
					22,000L		Minnesota-biologics-plant
	Takeda	Manufacture (biologics)	IV (cell based)	Unknown	215,000 sq ft	Brooklyn Park	
							https://www.biopharma-reporter.
	Takada	Manufacture (biologics)		Unknown	4x2000L	Lexington / Cambridge	com/Article/2014/02/18/Shire-s-single-use-site-
	Takeda	anaracare (biologics)	IV or PS (egg based,	SARIOWII	MEGOOL	Loxington / Gambridge	receives-US-FDA-approval-to-make-VPRIV https://www.biopharmadive.com/news/sanofi-
			cell based and				upgrades-biotech-manufacturing-with-new-
	Sanofi Pasteur	Manufacture (biologics)	recombinant)	Unknown	100,000 sq ft	Framingham	massachusetts-plant/565061/
				l	140,000ft ²	Swiftwater,	https://www.pharmaceutical-technology.
	Sanofi Pasteur	Manufacture (vaccines)	IV	Unknown	170 million influenza vaccine doses	Pennsylvania	com/projects/sanofipasteurvaccine/
							https://us.gsk.com/en-us/media/press-releases/gsk- invests-100-million-to-expand-long-term-vaccine-
							manufacturing-capabilities-in-hamilton-mt/
						Hamilton, Montana	https://www.epa.gov/sites/production/files/2020-
	GlaxoSmithKline (GSK)	Manufacturing (adjuvant)	Not specified	Unknown	Large	North Carolina Rockville	12/documents/gsk- hamilton_fact_sheet_mtpf00103.pdf
	(0010)				- 5-		https://www.virginiabusiness.com/article/merck-
	Merck & Co.	Manufacturer (vaccines)	VLP (currently HPV)	Unknown	1.2million sq ft	Rockingham	plans-1-billion-expansion-in-rockingham/
		Manufacturer (vaccines					https://jobs.merck.com/us/en/west-point-
	Merck & Co.	and biologics)		Unknown	Largest Merck manufacturing facility	West Point, PA	<u>pennsylvania</u>
		Manufacturer (early store					https://idt-biologika.com/idt-biologika-awarded-new-
		Manufacturer (early stage clinical samples and late				Rockville	task-order-in-the-scope-of-10-year-nih-contract-to- manufacture-vaccines-and-biologics-for-infectious-
	IDT Biologika	stage)	VVnr	Unknown	Unknown	Prev. contract with NIH	diseases
	Bristol-Myers Squibb	Manufacturer		Unknown		Devens	
	Ritedose (partner with			l			
	ApiJet)	Fill and Finish		45 million doses per month	1	Columbia, S.C	
	AbbVie CMO	Manufacturer (biosimilars)		Unknown		Puerto Rico, Barceloneta	
	ADD VIE CIVIO	manuacturer (DIOSIIIIIIafS)		GIRAOWII	32,000 sq. ft. Cell Therapy clinical	Darveiorieta	
					facility. 8 clean rooms, 3 process		
	L	l		l	development labs, and quality control	l	https://www.catalent.com/our-locations/north-
	Catalent Inc.	Manufacturer (biosimilars)		Unknown	labs.	Houston	america/houston-usa/
	Catalant Inc	Manufactures (viral vector)		Linkanua	120,000 # 2	Daltimore	https://www.catalent.com/our-locations/north-
	Catalent Inc.	Manufacturer (viral vector)		Unknown	128,000+ ft. 2	Baltimore	america/baltimore-usa/ https://www.catalent.com/our-locations/north-
							america/rockville-usa/
						Rockville	https://www.catalent.com/our-locations/north-
	Catalent Inc.	Manufacturer (viral vector)		Unknown	50,000+ ft2	Gaithersburg	america/gaithersburg-usa/
	Catalent Inc.	Manufacturer (biosimilars)		Linknown	Mammalian cell line engineering	Madison	https://www.catalent.com/our-locations/north-
	Catalent Inc.	Manufacturer (biosimilars)		Unknown	Confirmed capacity (plasmid &	Madison	america/madison-usa/
					perhaps more):		https://bioprocessintl.com/bioprocess- insider/facilities-capacity/vgxi-buys-site-and-starts-
							designing-gene-therapy-and-dna-vaccine-plant/
					Capabilities in DNA vaccine		https://bioprocessintl.com/bioprocess-
					manufacturing and non-GMP production og RNA. Has existing		insider/facilities-capacity/vgxi-adds-rna-suite-to-tap- growing-cell-and-gene-therapy-market/
					capacity and a new manufacturing	Multiple sites in Texas -	https://vgxii.com/vgxi-celebrates-grand-opening-of-
	VGXI	Manufacturer (biosimilars/DNA plasmid)	DNA & RNA	Linkanua	facility under construction. Interested in new clients.	Houston, Conroe, Woodlands	new-flex-scale-production-plant-for-gmp-rna-and-
	VOXI	(biosimilars/DNA plasmid)	DIVA & KIVA	Unknown	in new cilents.	vvoodiarius	dna-therapeutics-manufacturing/
							https://nantkwest.com/immunitybio-immunitybio- selected-for-operation-warp-speed-to-develop-
							novel-adenovirus-covid-19-vac/
						Torrey Pines/Culver	Currently developing Ad5-Covid-S/N candidate funded by OWS, but have manufacturing capacity.
						City/El Segundo	In phase II trials.
	Nantkwest	Manufacturer (adenovrirus)		Unknown	100 million doses by year-end	California	Subsidiary of NantWorks
							https://www.contractpharma.
	Aji Bio-Pharma	Manufacturor		Hoknown	Ajility platform - accelerate	San Diogo, California	com/contents/view_breaking-news/2020-06-
	AJI DIO-PIIAIIIIA	Manufacturer		Unknown	manufacturing process	San Diego, California	30/ajinomoto-bio-pharma-launches-ajility/ https://www.genopis.com/uncategorized/03-16-20-
							covid-19-vaccine-manufacturing-capacity/
							https://www.prnewswire.com/news-
							releases/genopis-plasmid-dna-manufacturer-in-
	Genopsis	Manufacturer		Unknown (small)	500L	San Diego, California	san-diego-to-launch-gmp-contract-manufacturing- business-300978458.html
United States	.,			. ()		.5.,	https://endpts.com/abzena-plots-6th-biologics-
United States	1	L		l	l.		plant-as-demand-for-mammalian-cell-line-
	Abzena	Manufacturer		Unknown	Large	San Diego, California	production-continues-to-grow/
					Confirmed capacity:		
					Argonaut is willing to talk to state and		
					federal govenrments to provide surge		
					support to help the scale-up of COVID-19 vaccine production. While		https://www.prnewswire.com/news-
					not the largest manufacturing facility,		releases/immediate-covid-19-vaccinetherapeutic-
	Argonaut	Manufacturer (incl. fill and		Linknown	they have availability from May 2021	Carlahad Calif	fillfinish-production-availability-announced-by-
	Argonaut	finish)		Unknown	onwards for formulation, fill & finish	Carlsbad, California	argonaut-manufacturing-services-301027920.html
	Roche (Genentech)	Manufacturer (biologics)		Unknown	90,000 liters. Large scale biologics manufacturer	Vacaville, California	https://www.gene.com/contact-us/visit- us/oceanside
	((biologico)				, comornia	https://www.siegfried.ch/drug-products
	Siegfried	Manufacturer (biologics)		Unknown	Unknown	Irvine, California	
					Up to 15,000L. 300,000 sq ft facility.		
					Mammalian Cell Culture		
					Stainless Steel and Single-Use Bioreactors		
	Baskstones I II I				Perfusion and fully continuous	E	https://www.bioxcellence.com/global-
	Boehringer Ingelheim	Manufacturer (biosimilars)		Unknown	manufacturing	Fremont, California	network/fremont
					500L single use and 1,000L stainless steel		
					Has the capacity to produce a protein		
					subunit vaccine. They have bioreactors available in second half		https://www.fiercepharma.com/manufacturing/joinn-
	JOINN Biologics	Manufacturer (biologics)		Unknown	of 2021	Richmond, California	biologics-nabs-60m-to-use-for-biologics-capacity
	·	` • ,			Confirmed capacity:	·	
					3,000L x2 + 2,000L x6 (Seattle)		
					2x 20,000L (Boulder)		
					Mammalian Cell Cultures		
					Most capacity in the near term is		
					being used, but some additional		
					capacity at Boulder facility. They		
					have many products in their pipeline. They do not expect that have much	Seattle	http://www.agcbio.com/facilities/seattle_facilities
	AGC Biologics	Manufacturer (biologics)		Unknown	remaining capacity	Boulder, Colorado	http://www.agcbio.com/facilities/seattle_facilities http://www.agcbio.com/facilities/boulder_facilities
•			•	•	•	•	

Country	Company	Function	Vaccine Platform	Production Quantity Estimate / Time	Notes on Production Capacity and Availability	Location	Sources
					Confirmed capacity:		
					Plasmid DNA, mRNA 70,000 sq ft		
	Aldevron	Manufacturer (biologics)		Unknown	Aldevron has the capacity to generate biolgics support for COVID- 19 workflows (plasmis DNA, RNA and proteins)	Fargo, North Dakota	https://www.nature.com/articles/d43747-020- 00631-1
	Novartis	Manufacturer (biologics)		Uknown		Longmount, Colorado Libertyville, Illinois	https://bioprocessintl.com/bioprocess- insider/facilities-capacity/novartis-opens-its-largest- gene-therapy-plant-to-support-zolgensma/
	КВІ	Manufacturer (biologics)		Unknown	Due for expansion in North Carolina 6 x 2000L bioreactors. Up by Q1 2022.	Boulder, Colorado	https://www.kbibiopharma.com/our-resources/kbi- biopharma-expands-us-operations
	Patheon (by Thermo Fisher)	Manufacturer (biologics, viral vectors) Fill-finish		Unknown	16x 2000L bioreactors in St Louis	St. Louis, Missouri Greenville, North Carolina	https://patheon.com/covid-19-mobilization/ https://patheon.com/viral-vector-services/ https://bioprocessintl.com/bioprocess- insider/facilities-capacity/patheon-doubling-global- biologics-capacity-50m-missouri-spend/
	Cognate Bioservices	Manufacturer (biologics)		Unknown	cGMP capacity. 80,000 sq ft.	Memphis, Tennessee Baltimore, Maryland	https://www.cognatebioservices.com/facilities#
	Alcami	Manufacturer (biologics)		Unknown		Wilmington, North Carolina	https://www.alcaminow.com/blog/alcami- announces-enhanced-laboratory-services-in- wilmington-nc-headquarters
	Biogen	Manufacturer (biologics)		Unknown	120,000L bioreactor capacity	RTP, North Carolina	https://www.fluor.com/projects/biogen-idec-biotech- manufacturing-epc
	GSK	Manufacturer (vaccines)		Unknown	Unclear - large	Rockville, Maryland	https://www.gsk.com/en-gb/media/press- releases/gsk-opens-new-global-vaccines-rd-center- in-rockville-md-usa/
	GSK	Manufacturer (biologics)		Unknown	Unclear - large. Cell cultures.	Upper Merion, PA	https://us.gsk.com/en-us/media/press-releases/gsk-invests-120-million-in-next-generation-us-biopharmaceutical-manufacturing-facility/
	AstraZeneca	Manufacturer (biologics)		Unknown	4x15,000L (at least)	Frederick, Marlyand	https://www.lifescienceleader, com/doc/astrazeneca-s-biologics-veteran-applying- a-risk-based-approach-to-plan-for-capacity-0001
	Novo Nordisk	Manufacturer		Unknown	195,000 square feet	West Lebanon, NH	https://www.novonordisk-us, com/content/dam/nncorp/us/en_us/homepage/abo ut-us/who-we-are/pdf/New%20Hampshire% 20Factsheet%202020.pdf
	Amgen	Manufacturer (biologics)			120,000 sq ft	West Greenwich, RI	https://www.prnewswire.com/news- releases/amgen-announces-rhode-island-will-be- location-of-first-us-next-generation- biomanufacturing-plant-300627393.html
	Rentschler	Manufacturer (mRNA + others)	RNA	Unknown		Milford, CT	https://www.rentschler-biopharma.com/about-us/
Viet Nam	Institute of Vaccines and Medical Biologicals	Manufacturer (influenza) Fill and Finish		Unknown		Nha Trang	http://en.ivac.com.vn/san-pham/1/vaccine/vien-vac- xin.html

Platform Acronym	Platform Description	Notable Vaccine Candidates
		Novavax: SARS-CoV-2 rS/Matrix M1-Adjuvant
		Instituto Finlay de Vacunas: FINLAY-FR anti-SARS-CoV-2 VAccine (R B D + adjuvant)
PS	Protein Subunit	CSL Ltd. + Seqirus + University of Queensland: MF59 adjuvant SARS-CoV-2 Sclamp vaccine
		AstraZeneca + University of Oxford: ChAdOx1-S - (AZD1222) (Covishield)
		Janssen Pharmaceutical: Ad26.COV2.S
		Gamaleya Research Institute - Health Ministry of the Russian Federation: GAM-COVID-Vac Adeno-based (rAd26-S+rAd5-S)
VVnr	Viral Vector (non-replicating)	CanSino: Recombinant novel coronavirus vaccines (adenovirus type 5 vector)
DNA	Deoxyribonucleic Acid	Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Sizhou) Biopharmaceutical Co., Ltd: INO-4800+electroporation
IV	Inactivated Virus	Sinovac Research and Development Co., Ltd: SARS-CoV-2 vaccine
		Pfizer/BioNTech: BNT162 (3 LNP-mRNAs)
		Moderna + NIAID: mRNA-1273
RNA	Ribonucleic Acid	CureVac AG: CVnCoV Vaccine
VVr	Viral Vector (replicating)	
		Serum Institute of India + Accelagen Pty + Spy Biotech: R B D SARS-COV-2 HBsAG VLP vaccine
VLP	Virus Like Particle	Medicago Inc.; Coronavirus-Like-Particle COVID-19 (CoVLP)
VVr + APC	Viral Vector (replicating) + Antigen Presenting Cell	
LAV	Live Attenuated Virus	
VVnr + APC	Viral Vector (non-replicating) + Antigen Presenting Cell	

Resource	URL	Notes
An open source-based map of COVID-19 candidate vaccines and manufacturing capacity.	http://vaxmap.org/	Edward Hammond
Potential LMIC vaccine manufacturers	https://www.dcvmn.org/Members-126	
UNICEF summary dashboard	https://www.unicef.org/supply/covid-19- vaccine-market-dashboard	
COVID-19 Vaccine Purchasing & Manufacturing Agreements	https://www.knowledgeportalia.org/covid19- vaccine-arrangements	